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ABSTRACT 
 
 
The nitrosourea drug lomustine is used clinically for treating a wide variety of 
malignancies, most commonly brain tumors and lymphoma. Lomustine undergoes hydrolysis in 
vivo to form isomeric metabolites, primarily trans-4-hydroxylomustine (trans-4) and cis-4- 
hydroxylomustine (cis-4) in various animal species including humans. Despite its widespread 
usage to treat canine lymphoma, the metabolism of lomustine has not been studied in dogs. It is 
reported that 4’-hydroxylation products of lomustine (trans-4 and cis-4) have enhanced alkylating 
activity and reduced toxic effects relative to lomustine, resulting in a better therapeutic index of 
each of the metabolites relative to the parent compound. Our results show that the metabolic profile 
of lomustine in dogs is similar to that in humans with trans-4 being the major metabolite and cis-
4 as the minor metabolite. Comparative cytotoxicity studies of lomustine and its trans-4 and cis-4 
metabolites in canine lymphoma cell lines 17-71 and GL-1 show that there is no difference in the 
cytotoxicity of the three compounds. In addition, a concentration and time-dependent cell killing 
was seen in both of these cell lines. Also primary canine cells like peripheral blood mononuclear 
cells (PBMC) from lymphoma dogs and canine hepatocytes for normal dogs did not show any 
sensitivity towards lomustine and its metabolites. 
  
Alkylation is thought to be the reason for the efficacy of lomustine while carbamylation 
has been implicated as the cause for the side effects seen with lomustine treatment such as 
hepatotoxicity. In the alkylation study we show that lomustine and its metabolites form similar 
levels of the DNA adducts N7 hydroxyethylguanine and O6 hydroxyethyldeoxyguanosine. These 
adducts may be used as molecular dosimeters of therapeutic response thus correlating to the similar 
cytotoxicity of these compounds. In terms of carbamylation, lomustine showed greater extent of 
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carbamylation in the canine hepatocytes and lymphoma cell lines. We hypothesize that if 
carbamylation of proteins is indeed one of the reasons for the side effects of lomustine, then using 
the metabolites instead may be a better option in terms of side effects. 
 
The DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) causes 
resistance of tumor cells to bifunctional nitrosoureas, like lomustine.  There is no data available 
regarding MGMT expression/activity in canine cells or tissues. Our study shows that there is low 
MGMT activity in the canine lymphoma cell line 17-71 while the GL-1 cells did not show any 
detectable enzyme activity or mRNA expression. The MGMT enzyme activity measured in canine 
hepatocytes is about 250-350 fmol/mg protein as compared to about 90 fmol/mg protein in 17-71 
cells. We also show that MGMT mRNA expression in 17-71 cells and canine hepatocytes 
positively correlates with its enzyme activity in these cells. 
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CHAPTER I 
 
Introduction 
 
1.1 Canine lymphoma 
 
Lymphoma is one of the most common hematopoietic neoplasias seen in dogs, accounting 
for up to 20% of all cancers diagnosed in canines (Vail et al., 2001). The disease more commonly 
occurs in middle age dogs but younger dogs are also known to be affected by it. Four anatomic 
forms of canine lymphoma have been described: multicentric, alimentary, mediastinal and 
extranodal (renal, central nervous system, cutaneous, ocular, bone, etc.) with multicentric being 
the most common anatomic form accounting for over 80% of all diagnosed cases (Madewell & 
Theilen, 1987). A common manifestation of multicentric lymphoma is the development of 
nonpainful generalized lymphadenopathy with peripheral lymph nodes often bilaterally and 
symmetrically enlarged (Meuten et al., 2008). Lymphoma is also classified based on the clonality 
of the lymphocytes involved, i.e. T-cell or B-cell. Diffuse large B-cell lymphoma accounts for 
majority of the lymphoma cases (Richards et al., 2013). 
 
Diagnosis of multicentric lymphoma involves physical examination for palpation of lymph 
nodes and obtaining tissue or cytological specimens for definitive diagnosis. For deep seated 
cancers, X-ray, ultrasound, bone marrow biopsy may be needed.  The WHO (Swerdlow et al., 
2008) has classified different stages of lymphoma based on the degree of metastasis and 
invasiveness as: 
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Stage I: Ailment restricted to single lymph node 
Stage II: Regional lymphadenopathy  
Stage III: Generalized lymphadenopathy 
Stage IV: Enlargement of the liver and spleen (with or without lymphadenopathy) 
Stage V: Bone marrow, central nervous system or involvement of other extranodal sites.  
 
The treatment approach for canine lymphoma is determined by the stage of the disease. 
The current standard of care for dogs with lymphoma involves the use of multiagent chemotherapy, 
which achieves response rates of 65% to 96% and first-remission durations of 6 to 9 months 
(Morrison, 2004). There are various multiagent chemotherapy protocols such as different 
variations of ‘CHOP’ (cyclophosphamide, doxorubicin, vincristine, prednisolone).  Despite 
favorable treatment outcomes initially, the majority of dogs will experience relapse, necessitating 
the reinstitution of additional chemotherapies for the management of refractory disease. Second 
remission is harder to achieve and may be of shorter duration (Moore et al., 1999). Some relapsed 
dogs become refractory to the initial treatment and hence may require a different chemotherapeutic 
agent/rescue therapy to achieve second remission. For rescue therapy, again a multiagent protocol 
is followed; however, a single agent therapy may be preferred for clients with financial or logistical 
restrictions. Also cross-resistance between chemotherapeutic agents can decrease the efficacy of 
rescue protocols. Alkylating agents seldom show cross resistance and are quite effective in 
achieving clinical remission (Tew et al., 2006). Alkylating agents include chemotherapeutic drug 
classes such as nitrosoureas, nitrogen mustards and alkyl sulfonates and function by attaching an 
alkyl group to the DNA.  
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The nitrosourea drug, lomustine (CCNU, CeeNU, C9H16ClN303, 1-(2-chloroethyl)-3-
cyclohexyl-1-nitrosourea), is used clinically for treating a wide variety of human malignancies, 
most commonly brain tumors and lymphoma (Mitchell & Schein, 1986; Tew et al., 1996). In 
veterinary medicine, lomustine has been successfully used primarily for the treatment of resistant 
lymphoma (Moore et al., 1999; Saba et al., 2007; Sauerbrey et al., 2007), but also for the treatment 
of mast cell tumors (Rassnick et al., 1999), intracranial meningioma (Jung et al., 2006), 
epitheliotropic lymphoma (Williams et al., 2006) and histiocytic sarcoma (Skorupski et al., 2007) 
in dogs either alone or in combination with other chemotherapeutic agents.  There are several 
studies in the literature indicating good efficacy of lomustine in combination with other 
chemotherapeutic agents such as L-asparaginase, doxorubicin, temozolamide, etc. for the 
treatment of resistant canine lymphoma (Moore et al., 1999; Saba et al., 2007; Sauerbrey et al., 
2007), however, its potential as a single agent for first line therapy or to treat relapsed canine 
lymphoma is less promising. In a study that evaluated the efficacy of lomustine and prednisolone 
as first line treatment of muticentric lymphoma,  9 out of 17 dogs showed complete or partial 
response with a median duration of remission of 39.5 days (range 20-130 days) (Sauerbrey et al., 
2007). In another study of lomustine as single agent chemotherapy for relapsed canine lymphoma 
in 11 dogs, 28% showed complete or partial remission with median response duration of 86 days 
(range 36-212 days) (Moore et al., 1999). However, lomustine as a single agent may be preferred 
when treatment costs prohibit exploring other options or when a multidrug treatment is not 
tolerated by the patient due to extreme side effects. 
 
In a clinical setting, lomustine is usually administered to dogs orally at 50-110 mg/m2 every 
three weeks (Kristal et al., 2004; Moore et al., 1999; Sauerbrey et al., 2007).  Lomustine is a highly 
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lipophilic nitrosourea compound, which undergoes hydrolysis in vivo to form isomeric 
metabolites, primarily trans-4-hydroxylomustine (trans-4) and cis-4-hydroxylomustine (cis-4) 
(Figure 1.1) in various animal species including humans (Hilton & Walker, 1975; Kastrissios et 
al., 1996; Lee et al., 1985). The comparative biological effects of lomustine and its metabolites 
were studied in mice. The single dose LD10 (dose causing death of 10% of the mice when 
administered intraperitonially) and single dose ED50 (dose producing 45 day survival in 50% of 
the mice after intraperitoneal implantation of 105  L1210 cells) were compared to determine the 
therapeutic index for each compound (Wheeler et al., 1977). The metabolites showed an 
approximately two-fold greater therapeutic index compared to the parent drug. It was therefore 
suggested that hydroxylation at the 4’-position of the cyclohexyl ring of lomustine, confers both 
isomers (cis-4 and trans-4) of the metabolite with enhanced alkylating activity and reduced toxic 
effects relative to lomustine, resulting in better therapeutic index of each of the metabolites relative 
to the parent compound (Wheeler et al., 1977). 
 
Hence it is plausible that the metabolites of lomustine could be better options for 
chemotherapy, with greater efficacy and favorable side effect profile than lomustine itself. In 
addition to the above metabolites, minor metabolites are also formed due to hydroxylation at the 
second and third position of the cyclohexyl ring (Hilton & Walker, 1975; Reed, 1984; Wheeler et 
al., 1977). However, there is no data available regarding the metabolism pattern of lomustine in 
dogs. 
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1.2 Side effects of lomustine 
 
One of the major toxic effects of lomustine in humans is delayed myelosuppression 
(Hoogstraten et al., 1973; Moertel et al., 1972). The hematological toxicity associated with 
lomustine is known to be dose-dependent with greater toxicity seen at higher doses. Another 
toxicity associated with lomustine treatment is hepatotoxicity, but unlike myelosuppression, these 
reactions are believed to be not dose-dependent or predictable.  Toxicity trials in healthy beagle 
dogs and clinical trials in tumor bearing dogs have shown lomustine to induce hepatotoxicity and 
myelotoxicity at doses that are clinically used (50-110 mg/m2 every three weeks) (Fulton & 
Steinberg, 1990; Kristal et al., 2004; Moore et al., 1999; Rassnick et al., 1999).   
 
The reported incidence of hepatotoxicity in dogs due to lomustine treatment is variable. 
Retrospective studies have reported elevation in liver enzymes in up to 86% of dogs receiving 
lomustine for cancer treatment (Kristal et al., 2004; Risbon et al., 2006; Williams et al., 2006) but 
only 3-6% of them showed clinical signs of serious liver injury. Another retrospective study 
concluded that elevation of alanine aminotransferase (ALT) is common during lomustine 
chemotherapy in dogs and that severe elevation can develop on a sudden onset not preceded by a 
mild ALT elevation (Hosoya et al., 2009). A prospective study of lomustine induced hepatotoxicity 
in tumor bearing dogs reported that out of 28 dogs that received lomustine as single agent 
chemotherapy, 7 dogs (25%) required discontinuation of lomustine due to severe elevation of ALT 
(Skorupski et al., 2007). In some rare cases fatalities due to terminal liver damage after lomustine 
treatment have also been reported (Williams et al., 2006). Based on the available data on this topic, 
it may be concluded that elevated ALT is a common occurrence following lomustine treatment, 
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however some dogs may show severe liver enzyme elevation and also clinical signs of liver injury 
necessitating discontinuation of lomustine. The underlying mechanism for hepatic injury due to 
lomustine is unclear. 
 
It is believed that chemical breakdown of lomustine, in addition to the alkylating 
intermediates, also produces isocyanates that carbamylate proteins and this may contribute to the 
side effects of lomustine (Babson & Reed, 1978; Lemoine et al., 1991; Reed, 1981; Sariban et al., 
1984). Carbamylation is a non-enzymatic post-translational modification of proteins that occurs 
due to binding of isocyanic acid to proteins and is usually associated with partial or complete loss 
of protein function (Lemoine et al., 1991). Although the highly reactive nature of the isocyanate 
species precludes their identification, lomustine derived isocyanates could participate in the 
chemotherapeutic and cytotoxic responses by inactivating enzymes some of which could be 
involved in vital functions of the cell such as replication and DNA repair. (Ducastelle et al., 1988; 
Fornace et al., 1978; Kann et al., 1974). It is thought that the metabolites of lomustine may be safer 
in terms of their side effects as compared to the parent drug, lomustine (Wheeler et al., 1977; Heal 
et al., 1978). The comparative carbamylating effects of lomustine and its major metabolites, have 
not been investigated in canine cells.  
 
1.3 Mechanism of action of lomustine and role of O6-methylguanine-DNA methyltransferase 
 
Like other nitrosoureas, lomustine and its metabolites lead to the covalent attachment of 
alkyl groups on the purine and pyrimidine bases of DNA. Although multiple adducts may be 
formed due to exposure to alkylating agents, not all adducts have the potential to cause permanent 
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DNA alteration. Of particular interest is the methyl adduct at the O6 position of guanine (Figure 
1.2) which causes mispairing and is associated with mutagenicity (Allay et al., 1999; Kadlubar et 
al., 1984; Swenberg et al., 1985). Adducts at the O6 position formed by chloroethylating 
compounds like lomustine cause inter-strand crosslinking in the DNA (Kohn, 1977). During DNA 
replication this crosslinking can ultimately lead to double strand breaks which is a potent inducer 
of apoptosis leading to cell death (Kaina et al., 2007; Ochs & Kaina, 2000). In addition to O6 
guanine, adducts at the N7 position of guanine (Figure 1.2) are formed in high concentration after 
nitrosourea exposure. In fact, N7 guanine adducts makes up 70-90% of the total adducts formed 
by alkylating agents (Rinne et al., 2005). However, they have not been implicated as a causal factor 
for mutagenesis like the O6 alkylguanine (Lawley, 1976; Pegg, 1977; Singer, 1975; Tong et al., 
1982). But due to its abundant formation following nitrosourea treatment, measuring the 
N7alkylguanine especially after exposure to low concentrations of lomustine and its metabolites 
(when other adducts may be below detection limits) can be used as a molecular dosimeter for 
therapeutic response or genotoxic drug exposure to cells.  
 
The direct repair of adducts at O6 guanine position is via the enzyme O6-methylguanine-
DNA methyltransferase (MGMT). MGMT is a DNA protective enzyme that is known to be present 
in the cytoplasm and nucleus of mammalian cells. The cytoplasmic MGMT is thought to be 
translocated to the nucleus rapidly in the event of DNA alkylation (Kaina et al., 2007). MGMT 
constitutes an evolutionary highly conserved DNA repair mechanism for the correction of O6-
guanine alkyl adducts.  While most other DNA repair pathways involve the combined action of 
multiple proteins, repair by MGMT is a direct reversal of damage, in which the offending alkyl 
group is transferred to a cysteine residue within the acceptor pocket of the MGMT protein 
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(Margison et al., 2003). This reaction is stoichiometric in nature i.e. one MGMT molecule will 
bind to a single adduct and will be directed to ubiquitination and cannot be reused, thus 
appropriately being called a ‘suicide enzyme’ (Kaina et al., 2007). Hence the cell’s capacity to use 
MGMT for repair of alkylation depends on the number of MGMT molecules already present and 
its ability for de novo synthesis. Due to the stoichiometry and autoinactivation mechanism, cells 
overwhelmed with alkylation can be depleted of MGMT and can be more susceptible to O6 
alkylating agents (Kaina et al., 2007) such as lomustine. 
 
This DNA repair enzyme (MGMT) plays a role in maintaining the integrity of the DNA in 
normal cells but also protects tumor cells against alkylating chemotherapeutic agents, resulting in 
drug resistance (Christmann et al., 2011).  MGMT is the major mechanism of resistance of tumor 
cells to bifunctional nitrosoureas, and its depletion with suicide inhibitors, such as O6 
benzylguanine, has been shown to repeatedly sensitize tumor cells to alkylating agents (Gerson, 
2002).  Previous studies have shown that mice deficient in MGMT gene are more susceptible to 
the toxic effects of alkylating anti-cancer agents (Sakumi et al., 1997), while in transgenic models, 
mice expressing increased levels of MGMT are more resistant to alkylating carcinogens (Dumenco 
et al., 1993; Nakatsuru et al., 1993). Although MGMT is ubiquitously expressed in all cells of the 
body, there is significant variation in its level in different tissues, the same tissues between 
individuals and also between neoplastic and non-neoplastic tissues (Christmann et al., 2011). Data 
from humans show that the liver cells have high MGMT activity while brain and bone marrow 
cells are known to have low MGMT expression (Christmann et al., 2011; Margison et al., 2003). 
This low MGMT level may be the reason for the dose dependent myelotoxicity seen with 
nitrosourea compounds (Maze et al., 1996). The MGMT level in different tumor cells is also 
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variable with certain tumors showing low level of MGMT like gliomas which explains the relative 
sensitivity of gliomas to alkylating anticancer agents (Christmann et al., 2011). However, the low 
MGMT in glioma cells is an average value with some gliomas completely lacking MGMT (Kaina 
et al. 2007), while in others the variability was over 10 fold (Bodell et al 2001). 
 
  Thus it is believed that MGMT may be playing a significant role in the efficacy of 
alkylating chemotherapeutic compounds in tumor tissue and also in the toxicity of these 
compounds in normal tissues. There is no data available regarding the MGMT levels in canine 
cells and tissues.  
 
The primary goal of this project was to study the metabolism of lomustine in dogs and to 
compare the cytotoxicity of lomustine and its major metabolites. Another goal was to measure the 
MGMT level in canine cells and to correlate it with the cytotoxicity of lomustine and its 
metabolites. The hypotheses were: 
1. Lomustine and its two major monohydroxylated metabolites (trans-4 and cis-4) have different and 
concentration dependent in vitro cytotoxic capabilities that are related to their ability to cause DNA 
alkylation and they also have different carbamylating activity on proteins.  
2. MGMT, a DNA repair enzyme, is negatively correlated with the cytotoxicity caused by lomustine 
and its metabolites in normal canine cells and also in canine lymphoma cell lines. 
 
Specific Aim # 1: To study the metabolism of lomustine in dogs and to compare the concentration 
dependent cytotoxicity of lomustine and its major metabolites in malignantly transformed canine 
lymphoma cell lines, peripheral blood mononuclear cells (PBMC) from lymphoma dogs and 
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normal canine hepatocytes. The comparative cytotoxic effects of lomustine and its metabolites in 
canine cells have not been investigated previously. We propose that the anticancer activities of 
lomustine are primarily exerted by the monohydroxylated metabolites. In addition, lomustine and 
its two major monohydroxylated metabolites may have different cytotoxic activities in canine 
primary cells and canine lymphoma cell lines. 
 
Specific Aim # 2: To compare the carbamylation caused by lomustine and its major metabolites 
in canine lymphoma cell lines and canine primary hepatocytes. This will test the hypothesis that 
the breakdown of lomustine and its metabolites produces reactive intermediates capable of 
carbamylating proteins. We will investigate the ability of these compounds to induce 
carbamylation in canine lymphoma cell lines and hepatocytes.  It is believed that carbamylation of 
proteins could contribute to the off-target toxicity of lomustine like hepatotoxicity. Also the 
metabolites of lomustine are thought to cause carbamylation to a lesser extent than parent 
lomustine.   
 
Specific Aim # 3: To detect and quantify O6 hydroxyethyldeoxyguanosine and N7 
hydroxyethylguanine adducts in canine lymphoma cell lines and canine primary hepatocytes 
exposed to lomustine, trans-4 and cis-4. The extent of DNA alkylation may act as a molecular 
dosimeter of therapeutic response and correlate with the cytotoxicity of lomustine and its 
metabolites. 
 
Specific Aim # 4: To measure the MGMT enzyme activity and mRNA expression in canine 
lymphoma cell lines and canine primary hepatocytes and to correlate it with the cytotoxicity of 
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lomustine and its metabolites.  This will help to determine whether or not the gene expression and 
enzyme activity of MGMT, a DNA repair enzyme, is negatively correlated with the cytotoxicity 
caused by lomustine and its metabolites in canine cells.  
 
In this dissertation, chapters 2-5 describe in detail the aforementioned aims of the study. 
Chapter 6 elaborates the overall conclusions of the study and also includes suggestions for future 
work based on the results obtained. 
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1.4 Figures and Legends 
Figure 1.1 Chemical structure of lomustine (A), trans-4-hydroxylomustine (B) and cis-4-
hydroxylomustine (C). 
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Figure 1.2 Schematic showing the N7 (A) and O6 (B) position of guanine 
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CHAPTER II 
 
Development of validated analytical method for detection of lomustine and its metabolites 
and metabolism characteristics of lomustine in dogs 
 
2.1 Introduction 
 
There are several studies in the literature indicating good efficacy of lomustine in 
combination with other chemotherapeutic agents for the treatment of resistant canine lymphoma 
(Moore et al., 1999; Saba et al., 2007; Sauerbrey et al., 2007).  Lomustine is usually administered 
to dogs orally at 50-110 mg/m2 every three weeks (Kristal et al., 2004; Moore et al., 1999; 
Sauerbrey et al., 2007).  One of the unique characteristics of lomustine is that it undergoes 
extensive first-pass hepatic metabolism to the geometric isomeric forms of a monohydroxylated 
metabolite in different animal species and humans (Kastrissios et al., 1996; Weinkam & Lin, 
1982). Wheeler et al. have concluded from their toxicity study in mice that the hydroxylation at 
the 4-position of the cyclohexyl ring confers both isomers (cis-4 and trans-4) of the metabolite 
with enhanced alkylating activity and reduced toxic effects relative to the lomustine, resulting in 
an approximately two-fold increase in the therapeutic index of each of the metabolite relative to 
the parent compound (Wheeler et al., 1977).  Unfortunately, metabolism of lomustine is associated 
with large interindividual variability. A reduction in the metabolism of lomustine to its 
hydroxylated isomeric forms is associated with a narrower therapeutic margin, and may manifest 
clinically as an increased risk of toxicity (Chang et al., 1993; Kastrissios et al., 1996). Although 
numerous studies have reported efficacy of lomustine for canine lymphoma, the metabolism of 
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lomustine has not been studied in dogs previously. In order to do that, we first developed an 
analytical method for the detection of lomustine and its monohydroxylated metabolites in canine 
plasma. 
 
Stability of the drugs is a major issue in such studies as nitrosoureas are known to be a 
highly labile class of drugs. For many of the drugs in this class, there is about 5% degradation 
when a solution is kept at room temperature in phosphate buffer saline or normal saline for 1 hour 
(Bosanquet, 1985). Also serum proteins are known to affect the stability of lomustine (Chatterji et 
al., 1978; Montgomery et al., 1967; Weinkam et al., 1980). It has been shown that human serum 
albumin has catalytic effect on lomustine thought to be due to the increased stress from distortion 
of bond angles of an already inherently unstable molecule (Weinkam et al., 1980). In aqueous 
media, lomustine gets rapidly ionized and undergoes uncatalyzed decomposition (Chatterji et al., 
1978). In our project, the stability study in methanol and plasma was very important as the stock 
solutions of lomustine and its metabolites and the blood/plasma samples from dogs that received 
lomustine may have to be stored for a few hours before analysis. In addition, to assess the in vitro 
cytotoxicity of lomustine and its metabolites in canine cells (elaborated in chapter 3), their stability 
in cell culture conditions had to be evaluated. 
 
In this chapter we first describe the development of an HPLC method for the quantitation 
of lomustine and its metabolites. We also describe studies to evaluate the stability of the 
compounds. In addition, the metabolism pattern of lomustine in dogs is evaluated.  
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2.2 Materials and Methods 
 
Analytical detection of lomustine and its monohydroxylated metabolites 
 
Sample preparation 
 
The monohydroxylated metabolites of lomustine, trans-4 (trans-(1-(2-Chloroethyl)-3-
(trans-4-hydroxycyclohexyl)-1-nitrosourea) and cis-4 (1-(2-Chloroethyl)-3-(cis-4-
hydroxycyclohexyl)-1-nitrosourea) were synthesized and purified by Obiter Research, LLC 
(Champaign, IL). A standard solution of 1 mg lomustine (Sigma-Aldrich), trans-4 and cis-4 was 
prepared in 1 ml HPLC grade ice-cold methanol.  Standards were prepared by the addition of a 
specified amount of lomustine, trans-4 and cis-4 in ice-cold methanol to blank canine plasma 
samples, 0.5 ml each, over a range from 25 to 5,000 ng/ml.  Phenytoin (Sigma-Aldrich) was used 
as an internal standard.  The internal standard was prepared in 1 ml ice-cold methanol (1 mg/ml) 
and diluted 1 to 10 in methanol to yield 100 ng/l standard solution.  To each sample, 20 l of 100 
ng/l internal standard was added.   
 
Extraction method 
   
Clean 16 × 150 mm Pyrex screw-cap culture tubes with polytetrafluoroethylene (PTFE) 
cap liners were silanized with trimethylchlorosilane (TMCS; Pierce Chemical) before use by 
rinsing them first with methanol, followed by a 5% solution of TMCS in hexane (Fisher Scientific). 
This step was followed by rinsing with methanol (Fisher Scientific) twice. The silanized tubes 
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were allowed to air-dry at room temperature. The analytical method used was as follows: Plasma 
samples (0.5 ml) were pipetted into 15-ml screw-cap tubes. Twenty µl of 100 ng/l internal 
standard was added to each tube, followed by 2 ml of dichloromethane.  The tubes were then vortex 
mixed for a few seconds, then centrifuged at 2000 rpm for 15 minutes.  The top aqueous layer was 
discarded off and the organic layer was transferred into clean tubes and dried under a stream of 
nitrogen at 20ºC in a water bath. The residue was reconstituted with 120 l of ice-cold methanol, 
vortex mixed briefly, and then transferred to an autosampler vial equipped with a 300 l spring-
loaded insert.  All samples were analyzed within 24 hours post-extraction. 
 
Instrumentation 
  
The HPLC procedure was adapted from that described by Lee et al. (Lee et al., 1985).  The 
instrument employed was Agilent HP 1100 HPLC system with quaternary solvent delivery pumps, 
vacuum degasser, thermostatted column compartment, 1100 series photodiode array detector and 
1100 series autosampler.  The column was an Inertsil ODS, 5 m particle size, 4.6 mm x 250 mm 
column size.  The mobile phase consisted of 34% acetonitrile in water (Solvent A), 44% 
acetonitrile in water (Solvent B), and 64% acetonitrile in water (Solvent C) run with a flow rate of 
0.8 ml/minute.  Samples were eluted by running two-step linear gradient commencing at the time 
of injection, with an initial condition of solvent A and proceeding to solvent B within 6 minutes, 
and then to solvent C within 8 minutes with a total running time of 30 minutes.  Acetonitrile (A998-
4, Fisher Scientific) and methanol (MX0488-1, EM Science) were HPLC grade.  The diode array 
detector was set up for single wavelength acquisition at 254 nm with a 12 nm span.  Injections 
were made with a 20 l sample loop. 
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Standard Curve Generation and Method Validation 
 
Standard curves were constructed by plotting standard lomustine, trans-4 and cis-4 
concentrations versus the ratio of lomustine, trans-4 and cis-4: internal standard peak areas.  
Standard curves were generated with Sigma Plot for Windows (Aspire Software International).  
The areas of peaks corresponding to lomustine, trans-4, cis-4 and internal standard were recorded, 
and the internal standard values thereby used to normalize the lomustine, trans-4 and cis-4 areas.  
Integrated peak values were entered into QuattroPro for Windows (Borland Software 
Coorporation, Scotss valley) for statistical analysis of standards and for calculation of amounts of 
lomustine, trans-4 and cis-4.  Each standard sample was run in duplicate.   
 
The quantitative HPLC method of lomustine, trans-4 and cis-4 was validated by examining 
the measurement of consistency of results (within-run and between-run), correlation (coefficient 
of determination of the standard curve), and extraction efficiency of the assay.  The within-run 
precision was calculated from similar responses from six repeats of three control samples (50, 500, 
2500 ng/ml) in one run.  The between-run precision was determined by comparing the calculated 
response (in ng/ml backfit of the standard curve) of the low (50 ng/ml), middle (500 ng/ml), and 
high (2500 ng/ml) control samples over three consecutive daily runs (total of six runs).  The assay 
accuracy for within-run and between-run was established by determining the ratio of calculated 
response to expected response for low (50 ng/ml), middle (500 ng/ml), and high (2500 ng/ml) 
control samples over six runs.  
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Standard curve correlation was measured by the mean coefficient of determination (r2) for 
six consecutive daily runs.  The extraction efficiency was determined by comparing the response 
(in area) of low (50 ng/ml), middle (500 ng/ml), and high (2500 ng/ml) standards, and the internal 
standard (2000 ng/ml) spiked into blank plasma eluent before evaporation to the equivalent 
extracted standards.  The lower limit of detection (LOD) was calculated utilizing the analyte’s 
peak height compared to the baseline noise.  By this method, the LOD was defined as the lowest 
concentration of analyte producing a peak greater than or equal to three times the baseline noise 
of the chromatogram.  
 
Stability studies 
 
Stability in methanol and canine plasma 
 
The stability of lomustine, cis-4 and trans-4 (1000 ng/ml, n=3) in methanol stored at room 
temperature, 4oC (refrigerated) and –20oC for 1, 3 and 7 days were investigated.  In this 
experiment, instrument responses from incubated samples were compared with that of freshly 
prepared samples using freshly prepared standard samples spiked with freshly prepared internal 
standard right before extraction.  The stability of lomustine, cis-4 and trans-4 in canine plasma 
samples were also investigated in refrigerated (4oC) and frozen samples (-20oC and -80oC) stored 
for 1, 3, 7 and 14 days (1000 ng/ml, n=3 for each experiment) 
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Stability in blood, plasma and culture media at 37ºC 
 
The drugs were added to culture media DMEM and L-15 canine whole blood and plasma 
at the concentration of 500 ng/ml and incubated at 37ºC. The drug concentration was measured at 
30 minutes, 1, 2, 4, 6 and 8 hours by HPLC. L-15 is a bicarbonate free media that is buffered by 
salts, amino acids and galactose. The culture media were supplemented with 10% FBS and 1% 
penicillin/streptomycin. Four replicates were used for each experiment. 
 
Metabolism characteristics of lomustine in dogs 
 
The in vivo metabolism characteristics of lomustine was studied in two research hounds. 
The dogs received 1.7 mg/kg (53.6 mg/m2) oral administration of commercially available 
lomustine capsules and blood samples were collected at 15, 30, 45 minutes, 1, 2, 4, 6, 8 and 12 
hours after drug administration. Lomustine was also administered orally to a lymphoma dog at the 
same dose and the concentration of lomustine and its metabolites were analyzed in the blood 
samples using the HPLC method described above. 
 
Red blood cell partitioning of lomustine and its metabolites 
 
Certain drugs that have greater lipophilicity may penetrate RBCs where it can be stored 
temporarily and this may bring down the plasma concentration of the drugs. Hence studying the 
RBC partitioning of drugs can help to select the appropriate matrix among whole blood, plasma 
or serum for assaying pharmacokinetic behavior of the drug (Hinderling, 1997). For this study, 
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commercially purchased canine whole blood in EDTA (The Veterinarians’ Blood Bank) was used. 
Two sets of blood samples (4 samples in each set, 1 ml/sample) were spiked with lomustine, trans-
4 and cis-4 at the concentration of 500 ng/ml. After incubating the samples at 37ºC for different 
time intervals, one set of blood samples was directly analyzed for drug concentration and in the 
other set, the plasma was separated and the drug concentration was measured in plasma. 
 
The concentration in RBCs was calculated as:  
CRBC= [(Cblood - Cplasma) x (1 - Hematocrit)] 
                              Hematocrit 
 
where Cblood and Cplasma are the concentrations of the drug in blood and plasma, respectively.  
Further the extent of partitioning of the drugs was measured by the following formula: 
 
Ke/p= Concentration of drug in RBC 
         Concentration of drug in plasma 
 
 
 
2.3 Results 
 
Analytical detection of lomustine and its monohydroxylated metabolites 
 
The HPLC diode array detection method reported here readily detects lomustine, cis-4 and 
trans-4 in canine plasma, with LOD of lomustine, cis-4 and trans-4 in plasma of about 10 ng/120 
µl, 5 ng/120 µl, and 5 ng/120 µl, respectively based on signal to noise ratio (data not shown).  The 
mean extraction efficiency values for lomustine, cis-4 and trans-4 were 73%, 89% and 90%, 
respectively from canine plasma samples on HPLC (Table 2.1).  The lomustine, cis-4 and trans-4 
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peak eluted at around 25 minutes (min) (0.3 min), 10.9 min (0.3 min), 10 min (0.3 min), 
respectively and the internal standard peak eluted at 13.4 min (0.3 min) (Figure 2.1).  
 
The resultant standard curve was curvilinear from 25 ng/ml to 5000 ng/ml for lomustine, 
cis-4 and trans-4 (Figure 2.2).  Both linear and curvilinear regression analysis were evaluated for 
generation of standard curves for lomustine.  Interestingly, back-calculated concentrations for each 
standard sample were within 20% of known amount sometimes when linear and sometimes when 
curvilinear regression analyses were used.   Therefore, based on back-calculated concentrations 
for each standard sample either curvilinear or linear regression analyses were used for the data 
evaluation.   
  
For within-run, the mean coefficient of variations (CV) were 5.1%, 1.9%, and 2.0% for 
lomustine, cis-4 and trans-4, respectively (Table 2.2).  In addition, the mean within-run accuracies 
for this method (n = 6 for each value) were 94.5%, 96.7% and 100.4% for lomustine, cis-4 and 
trans-4, respectively (Table 2.2).  For between-run, the mean CV were 10.9%, 8.5%, and 5.7% for 
lomustine, cis-4 and trans-4, respectively (Table 2.3).  The mean between-run accuracies for this 
method (n = 6 for each value) were 97.3%, 99.2%, and 101.7% for lomustine, cis-4 and trans-4, 
respectively (Table 2.3).  
 
Stability studies 
 
 
 
Results of HPLC analysis demonstrated 105 ± 6.0%, 98 ± 1.5% and 92 ± 3.7% recovery of 
lomustine, cis-4 and trans-4, respectively stored in methanol at room temperature for 24 hours 
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(n=3 for each compound) (Table 2.4). Here, 6.0%, 1.5% and 3.7% denotes the respective percent 
standard deviations (SD).  The stability studies in methanol demonstrated 111 ± 0.3% (SD), 103 ± 
0.6% (SD) and 100 ± 1.1% (SD) recovery and 110 ± 0.1% (SD), 102 ± 0.6% (SD) and 99.7 ± 0.8% 
recovery of lomustine, cis-4 and trans-4 in refrigerated and frozen (-20oC) samples, respectively 
stored for 24 hr (Table 2.4).  The stability of lomustine, cis-4 and trans-4 in refrigerated and frozen 
(-20oC) samples were 110 ± 3.9% (SD), 101 ± 4.7% (SD) and 100 ± 0.8% (SD), and 107 ± 0.1% 
(SD), 111 ± 0.5% (SD) and 102 ± 0.8%, respectively stored in methanol solution for 3 days (Table 
4).  The stability of lomustine, cis-4 and trans-4 in refrigerated and frozen (-20oC) samples were 
108 ± 0.6% (SD), 80.9 ± 0.4% (SD) and 94 ± 0.1% (SD), and 108 ± 2.2% (SD), 81.5 ± 0.3% (SD) 
and 96 ± 0.4%, respectively stored in methanol solution for a week (Table 2.4).   
 
Results of HPLC analysis demonstrated 71 ± 0.8% (SD), 95 ± 2.3% (SD) and 76 ± 0.6% 
recovery in refrigerated, 81 ± 1% (SD), 109 ± 2.3% (SD) and 89 ± 4.2% recovery in –20oC, and 
81 ± 1.0% (SD), 103 ± 8.3% (SD) and 88 ± 3.3% recovery in –80oC samples of lomustine, cis-4 
and trans-4, respectively stored in plasma for 24 hours (n=3 for each compound) (Table 2.5).   
 
The stability studies in canine plasma demonstrated 37 ± 0.8% (SD), 80 ± 1.8% (SD) and 
70 ± 1.3% (SD) recovery in refrigerated, 72 ± 3.2% (SD), 97 ± 2.7% (SD) and 119 ± 4.5% recovery 
in –20oC, and 81 ± 3.5% (SD), 93 ± 1.5% (SD) and 111 ± 5.9% recovery in –80oC samples of 
lomustine, cis-4 and trans-4, respectively, stored for 3 days (Table 2.5).  The stability of lomustine, 
cis-4 and trans-4 in canine plasma stored for a week in refrigerator were 20 ± 1.1% (SD), 26 ± 
1.5% (SD) and 16 ± 1.1% (SD), respectively, in –20oC samples were 73 ± 3.8% (SD), 79 ± 1.9% 
(SD) and 68 ± 0.9%(SD), respectively, in –80oC samples were 83 ± 9.3% (SD), 72 ± 2.4% (SD) 
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and 79 ± 1.5%, respectively.  The stability of lomustine, cis-4 and trans-4 in canine plasma stored 
for two-week in refrigerator were 7 ± 0.1% (SD), 7 ± 1.9% (SD) and 14 ± 1.7% (SD), respectively, 
in –20oC samples were 62 ± 0.9% (SD), 77 ± 2.2% (SD) and 83 ± 0.2, respectively, in –80oC 
samples were 69 ± 0.8% (SD), 88 ± 4.0% (SD) and 89 ± 2.1%, respectively.   
 
The stability studies indicated that lomustine and its two monohydroxylated metabolites 
are relatively stable in methanol solution at room temperature for 24 hours.  Lomustine and its 
metabolites are also relatively stable in methanol solution both in refrigerated and frozen (-20oC) 
samples for up to a week.  Based on our data, cis-4 seems to be less stable than lomustine and 
trans-4 in methanol solution when stored for a week in refrigerated and frozen (-20oC) samples. 
 
In the present study, the stability data indicated less stability of lomustine and its 
metabolites in canine plasma samples than in methanol solution especially in refrigerated samples.  
For example, we only had 37 ± 0.8% (SD), 80 ± 1.8% (SD) and 70 ± 1.3% (SD) recovery in 
refrigerated canine samples of lomustine, cis-4 and trans-4, respectively stored only for 3 days.  
Based on the data, the best recovery was obtained when canine plasma samples were stored at -
80oC.    
 
The results of the stability study at 37ºC show that lomustine and its metabolites degrade 
in the culture media, blood and plasma at 37ºC, the degradation process being quickest in DMEM 
(Figure 2.3). Lomustine, trans-4 and cis-4 seem to be more stable in the bicarbonate free media L-
15 as compared to DMEM. Lomustine and its metabolites were only detected up to 2 hours in the 
culture media and 4 hours in whole blood and plasma. The results indicate that in cell culture 
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conditions, there is rapid breakdown to lomustine and its metabolites and that the drugs may not 
be detected beyond 3-4 hours. 
 
Metabolism characteristics of lomustine in dogs 
 
Lomustine was not detected in plasma samples of the three dogs following oral 
administration of the drug. Figure 2.4A shows that trans-4 is the major metabolite of lomustine 
and the maximum concentration was about 325 ng/ml detected 1 hour after drug administration 
for both the research hounds. The maximum concentration of cis-4 in the three dogs was around 
40-65 ng/ml (Figure 2.4B).   
 
Red blood cell partitioning of lomustine and its metabolites 
 
The results show that there is a minor partitioning of these drugs into/onto RBC (Table 
2.6). About 9-15% of the drug was found to be in the RBC compartment. For our metabolism 
studies, drug concentrations were measured in plasma and not whole blood. This small difference 
in the drug levels in plasma and whole blood could have led to a slight underestimation of the 
actual drug concentrations in blood. 
 
2.4 Discussion 
 
Lomustine has been identified as a potentially important therapeutic agent for use in the 
treatment of various cancers in dogs; as such we needed a sensitive and reliable analytical method 
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to perform pharmacokinetic experiments with this agent in dogs.  In particular, the method selected 
needed to be sufficiently sensitive to detect low concentrations of lomustine and its possible 
monohydroxylated metabolites in canine plasma from test animals. 
 
The resultant HPLC method is a sensitive analytical method with the LOD of lomustine, 
cis-4 and trans-4 in plasma of about 10 ng/120 µl, 5 ng/120 µl, and 5 ng/120 µl, respectively based 
on signal to noise ratio.  Additionally, satisfactory recovery was obtained for lomustine and its 
monohydroxylated metabolites extracted from plasma samples.  The developed extraction 
procedure is very simple (one step liquid/liquid extraction procedure) and suitable to analyze 
multiple samples in a short-time period.  Additionally, with the mentioned HPLC method, we were 
able to separate chromatographic peaks of cis-4 and trans-4 isomers by almost 1 minute.  The CV 
for within-run and between-run samples were less than 15% for lomustine, trans-4 and cis-4 
indicating good method precision. 
 
The stability studies indicated that lomustine and its two monohydroxylated metabolites 
are relatively stable in methanol solution at room temperature for 24 hours and also when 
refrigerated and frozen (-20oC) for up to a week. In the present study, the stability data indicated 
less stability of lomustine and its metabolites in canine plasma samples than in methanol solution 
especially in refrigerated samples. Based on the data, the best recovery was obtained when canine 
plasma samples were stored at -80oC.   Due to stability issues, unknown canine samples following 
administration of lomustine should be stored at -80oC and should be analyzed within a week for 
better accuracy when determining the pharmacokinetic parameters of lomustine in dogs. 
 
32 
 
Lomustine is known to be an unstable compound and various factors accelerate the process 
of degradation. At around pH 6 and above, there is a drastic increase in degradation of lomustine 
in aqueous buffer (Loftsson & Fridriksdottir, 1990). Another study looked at the stability of 
lomustine in different culture media at 37ºC and found that in media that contain bicarbonate, the 
half-life of lomustine is lower than that of in bicarbonate free media (Lemoine et al., 1991). 
Presence of serum in the media also has a lowering effect on the half-life of lomustine (Weinkam 
et al., 1980). The above data suggest that physiological body conditions are not conducive for the 
stability of lomustine and its metabolites. After first pass metabolism, lomustine forms the 
hydroxylated metabolites (trans-4 and cis-4) that are more water soluble but these metabolites are 
also very unstable (Lemoine et al., 1991). It is believed that lomustine and its metabolites form 
extremely reactive alkylating intermediates, like carbonium ions, which are responsible for the 
cytotoxic effects of the drug (Heal et al., 1978; Lemoine et al., 1991). 
 
The metabolic profile of oral lomustine in dogs in our study is similar to that reported in 
humans and rats with trans-4 being the major metabolite followed by cis-4 and the complete 
absence of parent lomustine. However, since the study was only done in three dogs, these results 
have to be considered as preliminary. In our study, the dogs received lomustine at the dose of 1.7 
mg/kg and the two research hounds showed similar peak levels of trans-4 (about 325 ng/ml), but 
the levels for the same in the lymphoma dog was lower. The peak cis-4 lomustine level was 
between 40-65 ng/ml. In a published study of four human patients that received lomustine at the 
dose of 4.1 mg/kg, parent lomustine was not detected in blood. The average peak concentration of 
trans-4 was 530 ng/ml and that for cis-4 was 320 ng/ml (Lee et al., 1985). In another study in 
human patients that used high dose lomustine (15 mg/kg), the peak plasma concentration detected 
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ranged between 410-2310 ng/ml for trans-4 and 180-1820 ng/ml for cis-4 (Kastrissios et al., 1996), 
a 5 and 10 fold difference between the maximum concentrations observed among patients, 
respectively. This supports the premise that there is a large interindividual difference in the 
metabolic profile of lomustine.  
 
As parent lomustine was not detected in the blood at any time after administration of the 
drug, the RBC partitioning behavior of lomustine and its metabolites was studied. The results 
showed that there is a minor partitioning of these drugs into RBC. But the RBC partitioning values 
are not high enough to explain why lomustine was not detected in plasma samples obtained from 
three dogs after oral lomustine dosing.  This study suggests that like in other animal species, the 
absence of lomustine in dogs’ plasma is most likely due to rapid “first pass” metabolism and not 
due to significant RBC partitioning.    
 
In conclusion, we have developed and validated relatively sensitive, simple and reliable 
HPLC method to detect and quantify lomustine and its two monohydroxylated metabolites for 
future pharmacokinetic/toxicokinetic studies of lomustine in dogs. This method was utilized to 
study the stability of compounds and also to measure the drug concentration in the dog blood 
samples. Lomustine and its metabolites are highly unstable and therefore consideration must be 
given to the stability of these compounds while storing and using them for experimental purposes.  
Finally, the metabolic profile of lomustine in dogs was studied and was found to be similar to that 
in humans.  
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2.5 Figures and Legends 
Figure 2.1 A typical HPLC chromatogram of trans-4-hydroxylomustine, cis-4-hydroxylomustine 
and lomustine with internal standard (phenytoin) in methanol as extracted from spiked sample 
(1000 ng/0.5 ml plasma).  Absorbance at 254 nm is plotted vs. retention time. 
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Figure 2.2 Typical calibration curves for cis-4-hydroxylomustine (A), trans-4-hydroxylomustine 
(B), and lomustine (C) extracted from canine plasma samples, indicating coefficient of 
determination (R2) of 0.998, 0.997 and 0.991, respectively.  "Instrument Response" on the x-axis 
refers to Area/internal Standard Area; "Concentration" on the y-axis is in ng/ml. 
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Figure 2.3 Stability of lomustine (A), trans-4-hydroxylomustine (B) and cis-4-hydroxylomustine 
(C) in canine whole blood, canine plasma and culture media DMEM and L15. The ‘X-axis’ 
represents time in minutes and the ‘Y-axis’ represents concentration in ng/ml. 
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Figure 2.4 Plasma concentration of trans-4-hydroxylomustine (A) and cis-4-hydroxylomustine 
(B) following single 1.7 mg/kg oral administration of lomustine in three dogs. 
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Table 2.1 Extraction efficiencies of HPLC assay used to quantify cis-4-hydroxylomustine, trans-
4-hydroxylomustine and lomustine in canine plasma samples. 
 
 
 
Theoretic 
Concentration 
(ng/ml) 
Extraction Efficiency 
(Cis-4-hydroxylomustine 
(%) (mean ± SD) (n = 5) 
Extraction Efficiency 
(Trans-4-hydroxylomustine 
(%) (mean ± SD) (n = 5) 
Extraction Efficiency 
(Lomustine (%) 
(mean ± SD) (n = 5) 
50 90 ± 3.5 87 ± 2.5 72 ± 8.1 
500 90 ± 3.4 90 ± 2.9 74 ± 3.5 
2500 91 ± 5.9 89 ± 6.1 73 ± 12.7 
Mean 90 89 73 
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Table 2.2 Within-run precisions of HPLC assay used to quantify lomustine and its metabolites in 
canine plasma samples. 
 
 
 
Compound Theoretic 
Concentration 
(ng/ml) 
Measured concentration 
(ng/ml; mean ± SD) 
(n = 6) 
Accuracy (%) 
(mean ± SD) 
Coefficient of 
Variation (%) 
Trans-4- 
hydroxylomustine 
50 
53 ± 1.6 106.2 ± 2.3 2.2 
500 496 ± 6.0 99.2 ± 1.2 1.2 
2500 2395 ± 66.3 95.8 ± 2.4 2.5 
 Mean 100.4 2.0 
Cis-4-
hydroxylomustine 
50 54 ± 1.4 107.1 ± 2.8 2.6 
500 
455 ± 5.9 90.8 ± 1.3 1.4 
2500 
2301 ± 42.3 92.3 ± 1.7 1.8 
 Mean 96.7 1.9 
Lomustine 50 54 ± 3.1 107.1 ± 6.3 5.9 
500 450 ± 15.3 90.1 ± 3.1 3.4 
2500 2158 ± 131.0 86.3 ± 5.2 6.1 
 Mean 94.5 5.1 
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Table 2.3 Between-run precisions of HPLC assay used to quantify lomustine and its metabolites 
in canine plasma samples. 
 
 
Compound Theoretic 
Concentration 
(ng/ml) 
Measured concentration 
(ng/ml; mean ± SD)  
(n = 6) 
Accuracy (%) 
(mean ± SD) 
Coefficient of 
Variation (%) 
Trans-4- 
hydroxylomustine 
50 
51 ± 3.0 101.5 ± 6.0 5.9 
500 519 ± 27.5 103.8 ± 5.5 5.3 
2500 2495 ± 144.0 99.8 ± 5.8 5.8 
 Mean 101.7 5.7 
Cis-4-
hydroxylomustine 
50 49 ± 4.0 97.7 ± 8.0 8.1 
500 
507 ± 50.0 101.3 ± 10.0 9.9 
2500 
2468 ± 186.4 98.7 ± 7.5 7.6 
 Mean 99.2 8.5 
Lomustine 50 51 ± 5.4 102.3 ± 10.8 10.5 
500 482 ± 58.5 96.5 ± 11.7 12.1 
2500 2326 ± 233.9 93 ± 9.4 10.1 
 Mean 97.3 10.9 
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Table 2.4 Stability of cis-4-hydroxylomustine, trans-4-hydroxylomustine and lomustine in 
methanol. 
 
 
Duration of 
Incubation 
Temperature % Recovery of Cis-4-
hydroxylomustine 
(Mean ± SD, n=3) 
% Recovery of Trans-
4- hydroxylomustine 
(Mean ± SD, n=3) 
% Recovery of 
Lomustine 
(Mean ± SD, 
n=3) 
24 hrs Room 
temperature 
98 ± 1.5 92 ± 3.7 
 
105 ± 6 
 
Refrigerated 103 ± 0.6 100 ± 1.1 111 ± 0.3 
 
-20oC 102 ± 0.6 
 
99.7 ± 0.8 110 ± 0.1 
3 days Refrigerated 101 ± 4.7 100 ± 0.8 110 ± 3.9 
 
-20oC 111 ± 0.5 102 ± 0.8 107 ± 0.1 
 
1 week Refrigerated 80.9 ± 0.4 94 ± 0.1 
 
108 ± 0.6 
-20oC 81.5 ± 0.3 96 ± 0.4 108 ± 2.2 
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Table 2.5 Stability of cis-4-hydroxylomustine, trans-4-hydroxylomustine and lomustine in canine 
plasma. 
 
 
Duration of 
Incubation 
Temperature % Recovery of Cis-
4- 
hydroxylomustine 
(Mean ± SD, n=3) 
% Recovery of 
Trans-4- 
hydroxylomustine 
(Mean ± SD, n=3) 
% Recovery of 
Lomustine 
(Mean ± SD, 
n=3) 
24 hours Refrigerated 95 ± 2.3 76 ± 0.6 
 
71 ± 0.8  
-20oC 109 ± 2.3 
 
89 ± 4.2 
 
81 ± 1 
-80oC 103 ± 8.3 
 
88 ± 3.3 81 ± 1 
3 days Refrigerated 80 ± 1.8 
 
70 ± 1.3 
 
37 ± 0.8 
-20oC 119 ± 4.5 
 
97 ± 2.7 
 
72 ± 3.2 
-80oC 111 ± 5.9 
 
93 ± 1.5 81 ± 3.5 
1 week Refrigerated 16 ± 1.1 
 
26 ± 1.5 
 
20 ± 1.1 
 
-20oC 68 ± 0.9 79 ± 1.9 
 
73 ± 3.8 
 
-80oC 72 ± 2.4 
 
79 ± 1.5 
 
83 ± 9.3 
 
2 week Refrigerated 7 ± 1.9 
 
14 ± 1.7 
 
7 ± 0.1 
 
-20oC 77 ± 2.2 
 
83 ± 0.2 
 
62 ± 0.9 
 
-80oC 88 ± 4.0 89 ± 2.1 69 ± 0.8 
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Table 2.6 In vitro concentrations of lomustine, trans-4-hydroxylomustine and cis-4-
hydroxylomustine (ng/ml) in whole blood, plasma and red blood cells. 
 
 
Drug  Plasma mean ± SD Whole blood mean ± SD RBC  Ke/p 
Lomustine 287 ± 27 310 ± 14 37.49 0.12 
Trans-4-
hydroxylomustine 
256 ± 41 273 ± 16 27.71 0.10 
Cis-4-hydroxylomustine 229 ± 12 254 ± 16 40.75 0.17 
*All samples spiked at 500 ng/ml.  Hematocrit for the blood sample was 0.38 (38%). 
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CHAPTER III 
 
Cytotoxicity of lomustine and its trans-4-hydroxylomustine and cis-4-hydroxylomustine 
metabolites in canine lymphoma cell lines and primary cells 
 
3.1 Introduction 
 
Lomustine is a highly lipophilic nitrosourea compound, which undergoes hydrolysis in vivo 
to form isomeric metabolites, primarily trans-4 and cis-4 in various animal species including 
humans (Hilton & Walker, 1975; Kastrissios et al., 1996; Lee et al., 1985). From our metabolism 
studies described in chapter 2, we conclude that this is true in dogs as well.  It is reported that 
hydroxylation at the 4’-position of the cyclohexyl ring of lomustine, confers both isomers (cis-4 
and trans-4) of the metabolite with enhanced alkylating activity and reduced toxic effects relative 
to lomustine, resulting in an approximately two-fold increase in the therapeutic index of each of 
the metabolites relative to the parent compound (Wheeler et al., 1977).  This may suggest that the 
metabolites might have advantage over lomustine for clinical use.  
 
Hepatotoxicity is known to be a side effect of lomustine treatment. Based on the published 
studies on this topic, it can be concluded that elevated ALT is a common occurrence following 
lomustine treatment (Hosoya et al., 2009; Kristal et al., 2004), however some dogs may show 
severe liver enzyme elevation and also clinical signs of liver injury necessitating discontinuation 
of lomustine (Hosoya et al., 2009). The mechanism by which lomustine causes hepatotoxicity is 
unclear.  
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The goal of this study was to compare the concentration and time-dependent cytotoxicity 
of lomustine and its trans-4 and cis-4 metabolites in canine cells. The study was done in canine 
lymphoma cell lines, PBMC from lymphoma dogs and canine primary hepatocytes. Hepatotoxicity 
is one of the side effects seen with lomustine and it is believed that the metabolites may have a 
better side effect profile as compared to parent lomustine (Wheeler at al., 1977). The primary aim 
of using PBMC from lymphoma dogs for cytotoxicity study is to determine if PBMC, which are 
primary cells, are more sensitive to lomustine and its metabolites as compared to the immortalized 
cell lines. We hypothesize that the PBMC may show greater cell killing with lomustine and its 
metabolites as compared to the canine lymphoma cell lines.  
 
3.2 Materials and Methods 
 
Cytotoxicity of lomustine and its metabolites in canine lymphoma cell lines and PBMC  
 
The canine lymphoma cell lines 17-71 (Steplewski et al., 1987; Suter et al., 2005) and GL-
1 (Nakaichi et al., 1996) and PBMC obtained from lymphoma dogs were used for this assay. 
 
Peripheral blood mononuclear cells (PBMC) isolation 
 
Blood samples were collected from 3 lymphoma dogs that were brought to the veterinary 
teaching hospital. The dogs did not have any prior history of being treated for lymphoma. Four 
milliliters of whole blood were collected into one 5 ml heparinized tubes. Procedure for isolation 
of PBMC from lymphoma dogs was as described by Lavergne et al. (Lavergne et al., 2006).  Tubes 
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were placed on ice immediately and PBMC were isolated using density centrifugation. Blood was 
kept on ice and cell isolation was begun within 30 minutes of venipuncture. Whole blood was 
diluted with two volumes of prewarmed (37ºC) HBSS with 5 mM EDTA. This was carefully 
overlaid on 5 ml of prewarmed (37ºC) Lymphocyte Separation Media (Cellgro). After 
centrifugation, the buffy coat was harvested and washed with 3–4 volumes of HBSS with 5 mM 
EDTA. Lysing buffer (2 ml; 15.5 mM NH4Cl, 10 mM KHCO3, 1 mM EDTA, pH 7.4) was added 
to pelleted cells to lyse the residual erythrocytes. After washing with HBSS with 5 mM EDTA, 
cells were re-suspended in PBS and an aliquot was used to quantitate viable cells using Trypan 
blue dye exclusion.  
 
Cytotoxicity assays 
 
Cytotoxicity was evaluated after 48 hours by XTT cell proliferation assay and Annexin-PI 
assay (flow cytometry). The cell lines 17-71 and GL-1 were grown and maintained at 37°C in 5% 
CO2, and cultures were passaged as necessary to maintain high cell viability (above 90%) in culture 
media DMEM supplemented with 10% FBS, 1% penicillin/streptomycin. The PBMC were 
maintained in culture media RPMI-1640 supplemented with 10% FBS, 1% 
penicillin/streptomycin. The cell viability was assessed by Trypan blue dye exclusion test. For the 
XTT assay, the cells were plated in 96 well plates at a density of 20,000 cells/well. The cells were 
exposed to fresh media (DMEM supplemented with 10% FBS, 1% penicillin/streptomycin for the 
cell lines and RPMI-1640 supplemented with 10% FBS, 1% penicillin/streptomycin for PBMC) 
containing varying concentrations of lomustine, trans-4, or cis-4 metabolites (300, 1000, 3000 and 
10,000 ng/ml). Staurosporine (1 µM for 24 hours) was used as positive control for apoptosis in 
49 
 
GL-1 cells and PBMC while PAC-1 (first procaspase-3 activating compound, 10 µM for 48 hours) 
was used as positive controls for apoptosis in 17-71 cells. The vehicle control was 0.1% methanol 
corresponding to the concentration of methanol present in each of the drug treated samples. Forty 
eight hours after drug exposure, the cytotoxicity was measured by using XTT Cell Proliferation 
Assay Kit (Promega). For the Annexin/PI assay, 100,000 cells were plated/well in a 12 well plate. 
The drug treatment protocol was similar to that in the XTT assay. In addition to the apoptosis 
controls, a necrosis control was also used which was Triton-X (0.03% for 10 minutes). At the end 
of 48 hours of incubation, the cells were stained using the Annexin V-FITC Apoptosis detection 
Kit (BD biosciences) and analyzed by flow cytometry (BD Accuri C6). The experiments were 
done 3 separate times in the lymphoma cell lines with two technical replicates used for each assay. 
The experiment was done on PBMC obtained from 3 lymphoma dogs (n=3) with two technical 
replicates for each assay. 
 
Time dependent cytotoxicity of lomustine and its metabolites 
 
In this experiment, the cytotoxicity of lomustine, trans-4 and cis-4 was measured in canine 
cell lines 17-71 and GL-1 and  primary canine hepatocytes  at 48, 96 and 144 hours after drug 
exposure in order to see if there was a time dependent cytotoxic effect of these drugs. 
 
Isolation of canine hepatocytes 
 
Hepatocytes were isolated from six dogs that were euthanized at the Champaign county 
animal control facility. Isolation of canine hepatocytes was done by the by the method of  Spotorno 
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et al. (Spotorno et al., 2006) with few modifications. Liver samples (about 25 grams) from freshly 
euthanized dogs were obtained aseptically and immediately transported in PBS to the lab. About 
10 grams of the sample were cut out from the center of the collected liver tissue and transferred to 
a petri dish containing PBS with 1% penicillin/streptomycin. The tissue was finely minced with 
scissors and washed a couple of times with PBS. The minced sample was transferred to a flask 
containing 100 ml of cold collagenase solution (Collagenase II, 300 units/mg, 500 ng/ml in HBSS-
HEPES buffer) and softly stirred for about 10 minutes. At the end of incubation, 10 ml of FBS and 
50 ml of ice cold HBSS were added. The suspension was filtered through a nylon cell strainer (100 
micron pore size) and the filtrate was centrifuged at 50 g for 5 minutes at 4ºC. The supernatant 
was discarded and the pellet washed twice with PBS with 1% penicillin/streptomycin and 
centrifuged twice at 150 g for 2 minutes each and the pellet suspended in 5 ml PBS. The cell 
suspension was layered over 15 ml cushion of 60% Percoll in PBS in a 50 ml polycarbonate tube 
and centrifuged at 70 g at 4ºC for 5 minutes. The supernatant was discarded and the pellet washed 
with PBS. Cell viability was determined by Trypan blue dye exclusion test. The cells were 
suspended in DMEM (supplemented with 10% FBS and 1% penicillin/streptomycin) at a density 
of 0.6 million/ml and were incubated at 37ºC for 48 hours to acclimatize and form a monolayer. 
After 48 hours the media was replaced by hepatocyte maintenance media (Triangle research Labs, 
NC) and were ready for cytotoxicity assays. No additional FBS or penicillin/streptomycin was 
added to the commercially purchased hepatocyte maintenance media. The maintenance media was 
changed every day.  
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Commercially purchased canine hepatocytes 
 
In addition, fresh plated canine hepatocytes (96-well plates) were purchased from Triangle 
research labs (Research Park, NC). The canine hepatocytes were purchased 2 separate times and 
were harvested from 2 separate dogs (n=2). Similar to the manually isolated hepatocytes, 
hepatocyte maintenance media (Triangle research Labs, NC) was used in these cells (without 
additional FBS or penicillin/streptomycin) and was replaced every 48 hours. 
 
Cytotoxicity assays  
 
The cytotoxicity of lomustine, trans-4 and cis-4 in canine cell lines 17-71 and GL-1 and 
primary canine hepatocytes was measured at 48, 96 and 144 after exposure to the drugs. The 
experimental set up was similar to that mentioned above for the 48 hour cytotoxicity in the canine 
cells. Since the cytotoxicity had to be measured for longer time, the media was partially changed 
every 48 hours in order to avoid acid build-up. Half of the maintenance media was replaced every 
48 hours by slowly aspirating the media from the top and replacing with the same volume of new 
media. At the end of 48, 96 and 144 hours, cytotoxicity was measured by XTT and Annexin/PI 
assay. For the Annexin/PI assay the hepatocytes were trypsinized as follows. After aspirating out 
all the media from the wells, about 20µl trypsin (0.25%) was added to each well and the plates 
were incubated at 37ºC for 1-2 minutes. After that time, DMEM containing 10% FBS was added 
to each well to inactivate the trypsin. The plates were returned to the incubator for 5 minutes. The 
cells were then washed with PBS and stained with Annexin V and PI (propidium iodide) for flow 
cytometry. Staurosporine (1 µM for 24 hours) was used as positive control for apoptosis. Two 
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technical replicates were used for each assay. For the lymphoma cell lines the experiments were 
done 3 separate times with two technical replicates used for each assay. The experiment was done 
in hepatocytes isolated from six dogs (n=6) and commercially purchased hepatocytes from two 
dogs (n=2). Two technical replicates were used for each assay. 
 
Statistical analysis 
 
Statistical analysis was done using SPSS software (IBM, NY). Descriptive statistics were 
produced for all continuous variables.  Mean and standard deviation were calculated.  Normality 
of data was assessed using the Shapiro-Wilks test.  Paired t-tests were performed to evaluate 
differences between technical repeats of each drug and dose combination.  Multiple one way 
ANOVAs and Tukey’s post hoc test were performed to evaluate the following within and between 
group differences: Between drugs within each dose in each cell type at each time point, between 
doses (concentrations) within each drug in each cell type at each time, between time points within 
dose in cell types for the each drug. The p value was set at 0.05. For the canine lymphoma cell 
lines, two out of seventy two groups did not show normal distribution using Shapiro-Wilks test. 
However when these groups were further evaluated for normality using kurtosis, skewness and Q-
Q plots, the data showed normal distribution. Hence a parametric test was used to reduce the 
probability of type II error. 
 
Power analysis: Cytotoxicity data from two canine lymphoma cell lines were used to 
estimate sample size requirements for PBMC. Using the data from the 17-71 and GL-1 cell lines, 
based on a priori information of alpha=0.05, power of 0.8 and expected difference in mean of 3.77 
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(corresponding to the maximum standard deviation seen at any concentration), we would require 
3 samples. The lowest concentration of 300 ng/ml was excluded from the power analysis as no 
statistically significant cell killing was seen in either of the cell lines with any of the drugs at that 
concentration. 
 
3.3 Results 
 
Cytotoxicity of lomustine and its metabolites in canine lymphoma cell lines and PBMC  
 
The results obtained from XTT assay show that there was significant cell killing at 3000 
and 10,000 ng/ml concentrations, as compared to control for lomustine, trans-4 and cis-4 
metabolites in canine lymphoma cell line 17-71(Figure 3.1). In the canine lymphoma cell line GL-
1, in addition to the above concentrations, 1000 ng/ml also showed significant cytotoxicity 
compared to the vehicle control. The Annexin/PI assay also showed similar pattern of reduction in 
cell viability. After treating the cells with the highest drug concentration, 10,000 ng/ml, about 50% 
and 40% of the cells were still viable at 48 hours in 17-71 and GL-1 cells respectively (Figure 3.2). 
The results obtained from both XTT and Annexin/PI assay do not show any significant difference 
in the cytotoxicity caused by lomustine, trans-4, and cis-4 in 17-71 and GL-1 cells at 48 hours. 
Lomustine and its metabolites did not show any cell killing in the PBMC obtained from three 
lymphoma dogs at 48 hours after exposure to lomustine, trans-4 and cis-4 (Figure 3.3). Our results 
show that terminally differentiated lymphocytes in circulation may not be as sensitive to alkylating 
agents like lomustine. It is also possible that PBMC may require longer incubation time for the 
cytotoxicity of lomustine to become apparent. 
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Time dependent cytotoxicity of lomustine and its metabolites 
 
All the three compounds showed a greater degree of cell killing at 96 and 144 hours as 
compared to 48 hours thus confirming the premise that cytotoxicity with these drugs is delayed in 
nature (Figures 3.4-3.7). However, no statistically significant difference was seen in the 
cytotoxicity among the three compounds. In the 17-71 cell, the 300 ng/ml samples did not show 
any cell killing or reduction in viability even at 144 hours after drug treatment. As evident from 
the results, the 3000 and 10,000 ng/ml concentration resulted in a comparable level of cell killing 
at 144 hours. Also, at 10,000 ng/ml at 96 hours, most of the cells were non-viable. Due to this 
‘saturation’ in cell killing very little difference was seen in cytotoxicity at 144 hours as compared 
to 96 hours at 10,000 ng/ml. These results show that there is a delay in cell killing brought about 
by lomustine and its metabolites and hence measuring cell viability/apoptosis after short 
incubation time may not be the best indicator of the cytotoxic potential of the compounds. 
 
The commercially purchased hepatocytes did not show any time or concentration 
dependent sensitivity to lomustine or its metabolites both by XTT and Annexin/PI assay (Figures 
3.8 and 3.9). The same was true for the hepatocytes that were isolated from the six dogs euthanized 
at the animal control facility (Figures 3.10 and 3.11). This may be suggestive that the primary cells 
are not as responsive to lomustine or its metabolites as compared to the cell lines.  
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3.4 Discussion 
 
As mentioned previously it has been reported that the major hydroxylated metabolites of 
lomustine may have enhanced alkylating activity and reduced toxic effects relative to parent 
lomustine (Wheeler et al., 1977). In this project we wanted to investigate, through in-vitro studies, 
if the major hydroxylated metabolites show potential as a more effective treatment option 
compared to lomustine. The metabolism studies discussed in chapter 2 show that trans-4 and cis-
4 are the major metabolites in dogs after oral treatment with lomustine, trans-4 being in greater 
proportion.  
 
The drug concentrations for the cytotoxicity study were derived from the metabolism 
studies in dogs where we found that the maximum concentration of trans-4 was about 300 ng/ml 
and that for cis-4 was 50 ng/ml. Hence we used log incremental concentrations starting at 300 
ng/ml up till 10,000 ng/ml as we did not know at what concentration the in vitro biological effects 
of the drugs would be seen. In our cytotoxicity study to evaluate the time dependent effect of 
lomustine and its metabolites, the culture media was partially changes every 48 hours. Stability 
studies in culture media (elaborated in chapter 2) showed that lomustine and its metabolites do not 
persist in the culture media and blood beyond 4 hours at 37ºC. Due to the short half-life of the 
drugs, changing the culture media every 48 hours would not be a confounding factor for comparing 
cytotoxicity at different time points. 
 
We found no significant difference in the cytotoxicity caused by lomustine and its trans-4 
and cis-4 metabolites in both the canine lymphoma cell lines 17-71 and GL-1. At 48 hours after 
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treatment with 10,000 ng/ml concentration of lomustine or its metabolites, 40-50 % of the cells 
were still viable. However, after 96 hours of incubation this number had dropped to about 20% 
indicating a time dependent effect of lomustine cytotoxicity. In the PBMCs from lymphoma dogs, 
none of the drugs showed any significant cell killing compared to the control at 48 hours after 
lomustine treatment.  Interestingly, the in-vitro IC50 concentration for lomustine mentioned in 
literature varies from 50-250 μM (11,650-58,400 ng/ml) (Astier et al., 2005; Shinwari et al., 2008; 
Wilkoff & Dulmadge, 1986). These studies have utilized different cell lines and also used different 
techniques of detecting the cell killing. However a systematic study of the time dependent nature 
of cell killing by lomustine has not been done before. Our finding may be suggestive that apoptosis 
of cells after lomustine administration is not an immediate event but rather a delayed one. This is 
also supported by the fact that peak neutropenia, which is a dose limiting side effect of lomustine 
treatment usually occurs 7-10 days after drug administration (Kristal et al., 2004; Moore et al., 
1999; Rassnick et al., 1999). 
 
Another aim of this study was to compare the cytotoxicity of the lomustine and its 
metabolites in primary hepatocytes from normal dogs. Published studies on lomustine inducted 
hepatotoxicity show that hepatotoxicity after lomustine treatment is very common and may also 
result in serious irreversible hepatopathy. A recent study published in 2009 that looked at ALT 
elevation after lomustine administration as single agent chemotherapy (Hosoya et al., 2009) puts 
the overall prevalence of major ALT elevation (>5-fold upper reference limit) at 29% (32 of 109). 
This developed most commonly after one to three doses of lomustine out of which 53% (17/32) of 
the cases occurred without preceding mild ALT elevation. Hence, to compare the cytotoxic 
potential of lomustine and its trans-4 and cis-4 metabolites in hepatocytes seemed promising as it 
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is thought that the metabolites may have lower side effects as compared to lomustine. In our study 
however, we were not able to verify this as none of the three compounds showed any apparent cell 
killing in the canine hepatocytes, the ones that were commercially purchased or isolated from 
euthanized dogs. 
 
One reason for the non-significant cytotoxic response in hepatocytes could be that primary 
cells that are non-replicating like hepatocytes in vitro, may require much longer time to show 
apparent cell killing with alkylating compounds. Nitrosoureas are known to form adducts on the 
DNA and primarily the adducts formed at the O6 position of guanine are thought to be toxic to the 
cells (Kaina, 2003; Ludlum, 1990; Sedgwick, 2004). During cell replication, this epigenetic 
modification may lead to double strand breaks which is known to be a potent inducer of apoptosis 
(Kaina, 2003; Kaina et al., 2007). This may explain why we did not see any cell killing in the 
hepatocytes even six days after lomustine treatment and also in the PBMCs which are terminally 
differentiated.  
 
From this study we conclude that there is no difference in the cytotoxicity of lomustine, 
trans-4 and cis-4 in two canine lymphoma cell lines 17-71 and GL-1. Longer incubation after drug 
exposure showed greater reduction in cell viability indicating a time dependent cell killing by all 
the three compounds. Also primary cells like PBMC and hepatocytes did not show any cell killing 
with lomustine or its metabolites and may require much longer time after drug exposure to show 
apparent cell killing. 
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3.5 Figures and Legends 
Figure 3.1 Graphs showing the results of XTT cell proliferation assay in 17-71 (A) and GL-1 (B) 
cells.VC refers to vehicle control which is 0.1% methanol. PAC-1 (10 µM) and staurosporine (1 
µM) were used as positive control for apoptosis for 17-71 and GL-1 cells, respectively. The results 
show mean and standard deviation of three independent experiments. * indicates statistical 
significant difference compared to vehicle control. (p=0.05) 
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Figure 3.2 Graphs showing the percent viable cells obtained from Annexin/PI assay in 17-71 (A) 
and GL-1 (B) cells. VC refers to vehicle control which is 0.1% methanol. PAC-1 (10 µM) and 
staurosporine (1 µM) were used as positive control for apoptosis for 17-71 and GL-1 cells, 
respectively. The results show mean and standard deviation of three independent experiments. * 
indicates statistical significant difference compared to vehicle control. (p=0.05) 
 
 
 
 
 
 
 
 
 
* * * 
* * * 
 
* * * 
* * * * * * 
(A) 
(B) 
60 
 
Figure 3.3 Graphs showing the results of XTT (A) and Annexin/PI (B) assays in PBMC isolated 
from three lymphoma dogs .VC refers to vehicle control which is 0.1% methanol. Staurosporine 
(1 µM) was used as positive control for apoptosis. The graphs show mean and standard deviation 
of results obtained from three dogs. No statistically significant difference was seen in any of the 
drug treated samples compared to vehicle control. 
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Figure 3.4 Graphs showing the result of XTT cell proliferation assay in 17-71 cells at 48 (A), 96 
(B) and 144 (C) hours after treatment with lomustine, trans-4-hydroxylomustine and cis-4-
hydroxylomustine. VC refers to vehicle control which is 0.1% methanol. PAC-1 (10 µM) was used 
as positive control for apoptosis. The results show mean and standard deviation of three 
independent experiments. * indicates significant difference compared to vehicle control. (p=0.05). 
Δ indicates significant difference compared to the same drug concentration at the immediately 
earlier time point. 
 
 
 
 
 
 
 
* * * 
* * * 
 
* * * 
* * * 
* * * 
Δ Δ Δ 
Δ Δ Δ 
 
* * 
* 
* * * 
* * * 
Δ 
Δ Δ 
Δ Δ Δ 
Δ Δ Δ 
(A) 
(B) 
(C) 
62 
 
Figure 3.5 Graphs showing the results of XTT cell proliferation assay in GL-1 cells at 48 (A), 96 
(B) and 144 (C) hours after treatment with lomustine, trans-4-hydroxylomustine and cis-4-
hydroxylomustine. VC refers to vehicle control which is 0.1% methanol. Staurosporine (1 µM) 
was used as positive control for apoptosis. The results show mean and standard deviation of three 
independent experiments. * indicates significant difference compared to vehicle control. (p=0.05). 
Δ indicates significant difference compared to the same drug concentration at the immediately 
earlier time point. 
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Figure 3.6 Graphs showing the results of Annexin/PI assay assay in 17-71 cells at 48 (A), 96 (B) 
and 144 (C) hours after treatment with lomustine, trans-4-hydroxylomustine and cis-4-
hydroxylomustine. VC refers to vehicle control which is 0.1% methanol. PAC-1 (10 µM) was used 
as positive control for apoptosis. The results show mean and standard deviation of three 
independent experiments. * indicates significant difference compared to vehicle control. (p=0.05). 
Δ indicates significant difference compared to the same drug concentration at the immediately 
earlier time point. 
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Figure 3.7 Graphs showing the percent viable cells obtained from Annexin/PI assay in GL-1 cells 
at 48 (A), 96 (B) and 144 (C) hours after treatment with lomustine, trans-4-hydroxylomustine and 
cis-4-hydroxylomustine. VC refers to vehicle control which is 0.1% methanol. Staurosporine (1 
µM) was used as positive control for apoptosis. The results show mean and standard deviation of 
three independent experiments. * indicates significant difference compared to vehicle control. 
(p=0.05). Δ indicates significant difference compared to the same drug concentration at the 
immediately earlier time point. 
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Figure 3.8 Graphs showing the results of XTT assay in commercially purchased canine 
hepatocytes at 48 (A), 96 (B) and 144 (C) hours after treatment with lomustine, trans-4-
hydroxylomustine and cis-4-hydroxylomustine. VC refers to vehicle control which is 0.1% 
methanol. Staurosporine (1 µM) was used as positive control for apoptosis. The graphs show mean 
and standard deviation of results obtained from two dogs. No statistically significant difference 
was seen in any of the drug treated samples compared to vehicle control. 
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Figure 3.9 Graphs showing the percent viable cells obtained from the Annexin/PI assay in 
commercially purchased canine hepatocytes at 48 (A), 96 (B) and 144 (C) hours after treatment 
with lomustine, trans-4-hydroxylomustine and cis-4-hydroxylomustine. VC refers to vehicle 
control which is 0.1% methanol. Staurosporine (1 µM) was used as positive control for apoptosis. 
The graphs show mean and standard deviation of results obtained from two dogs. No statistically 
significant difference was seen in any of the drug treated samples compared to vehicle control. 
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Figure 3.10 Graphs showing the results of XTT assay in hepatocytes from six dogs at 48 (A), 96 
(B) and 144 (C) hours after treatment with lomustine, trans-4-hydroxylomustine and cis-4-
hydroxylomustine. VC refers to vehicle control which is 0.1% methanol. Staurosporine (1 µM) 
was used as positive control for apoptosis. The graphs show mean and standard deviation of results 
obtained from six dogs. No statistically significant difference was seen in any of the drug treated 
samples compared to vehicle control. 
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Figure 3.11 Graphs showing the percent viable cells obtained from the Annexin/PI assay in 
hepatocytes from six dogs at 48 (A), 96 (B) and 144 (C) hours after treatment with lomustine, 
trans-4-hydroxylomustine and cis-4-hydroxylomustine. VC refers to vehicle control which is 0.1% 
methanol. Staurosporine (1 µM) was used as positive control for apoptosis. The graphs show mean 
and standard deviation of results obtained from six dogs. No statistically significant difference was 
seen in any of the drug treated samples compared to vehicle control. 
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CHAPTER IV 
 
Alkylating and carbamylating effects of lomustine, trans-4-hydroxylomustine and cis-4-
hydroxylomustine in canine lymphoma cell lines and hepatocytes 
 
4.1 Introduction 
 
It is known that nitrosoureas decompose at physiological conditions to yield alkylating and 
carbamylating intermediates (Montgomery et al., 1967), however the relative contribution of these 
events to the toxicity and therapeutic effects are unclear (Wheeler et al., 1974). Decomposition of 
lomustine in aqueous produces chloroethyl carbonium ion which is an alkylating intermediate and 
also cyclohexyl isocyanate which is a carbamylating agent (Colvin et al., 1976; Weinkam et al, 
1980; Wheeler et al., 1975). 
 
Alkylating agents bind to the DNA at various sites based on the relative electrophilicity 
and nucleophilicity. These compounds are electrophilic in nature and attack the nucleophilic sites 
on the DNA to form an alkylated product (Ludlum, 1990). The N7 position of guanine is the most 
reactive site (Boysen et al., 2009; Ludlum, 1990) with all alkylating agents and hence about 70-
90% of the adducts are formed at this position (Sedgwick, 2004; Rinne et al., 2005). However the 
relative mutagenicity and carcinogenicity of alkylating agents correlate with the reagents ability 
to bind to oxygen sites (Beranek, 1990; Singer, 1985). Chloroethylating compounds like lomustine 
form adducts at the O6 position of guanine (Sedgwick, 2004). If not repaired, these adducts form 
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DNA interstrand cross links (Ludlum, 1990) which may lead to double strand breaks and 
ultimately, apoptosis of the cell (Kaina, 2003). 
 
In our cytotoxicity study (elaborated in chapter 3), lomustine and its metabolites showed 
similar degree of cell killing in the canine cell lines 17-71 and GL-1 and hepatocytes. As alkylation 
is thought to be the main reason for the cytotoxic effects of these drugs (Ludlum, 1990), we wanted 
to investigate if the compounds have similar pattern of alkylation. It is believed that the 
concentration of an internal dosimeter such as DNA adducts is a more accurate measure of the 
amount of mutagen reaching the target site than the applied dose (Beranek, 1990).  In a recent 
study published, it was shown that N7 hydroxyethylguanine and O6 hydroxyethyldeoxyguanosine 
are some of the main DNA alkylation products formed after exposure to chloroethylating agents 
(Bodell, 2009).  
 
It is believed that the dominant role of carbamylating activity is in determining the toxicity 
of compounds which may be manifested as side effects (Wheeler et al., 1974). The isocyanate 
intermediates formed by the breakdown of lomustine react with the lysine residues in protein 
leading to post translational modification of proteins (Lemoine et al., 1991). This could result in 
partial or complete loss of protein function (Jaisson et al., 2011). The amount of isocyanates 
produced can vary depending on the chemical structure of the compound which may result in 
variable degree of carbamylation of intracellular proteins (Schmall et al., 1973; Wheeler et al., 
1974). Carbamylation of proteins is believed to contribute to the side effects seen with lomustine 
(Wheeler et al., 1974).  
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It is reported that the cis-4 and trans-4 metabolites of lomustine may have reduced toxic 
effects relative to lomustine (Wheeler et al., 1977) and therefore the metabolites might have 
advantage over lomustine for clinical use (Heal et al., 1978). The aim of this study was to compare 
the alkylation and carbamylation potential of lomustine and its trans-4 and cis-4 metabolites in 
canine lymphoma cell lines and hepatocytes. The O6 hydroxyethyldeoxyguanosine and N7 
hydroxyethylguanine adducts was measured by LC/MS/MS and the carbamylation was assessed 
by ELISA. 
 
4.2 Materials and Methods 
 
DNA adduct detection assay 
 
The O6 hydroxyethyldeoxyguanosine and N7 hydroxyethylguanine adducts were measured 
in canine lymphoma cell lines 17-71 and GL-1 and primary canine hepatocytes (isolated from six 
dogs that were euthanized at the Champaign county animal control facility) after exposure to 
lomustine, trans-4 and cis-4 by the LC/MS/MS method as mentioned above. The lymphoma cell 
lines were grown and maintained at 37°C in 5% CO2, and cultures were passaged as necessary to 
maintain high cell viability (above 90%) in culture media DMEM supplemented with 10% FBS, 
1% penicillin/streptomycin. 
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Isolation of canine hepatocytes 
 
Hepatocytes were isolated from six dogs that were euthanized at the Champaign county 
animal control facility. Isolation of canine hepatocytes was done by the by the method of  Spotorno 
et al. (Spotorno et al., 2006) with few modifications. Liver samples (about 25 grams) from freshly 
euthanized dogs were obtained aseptically and immediately transported in PBS to the lab. About 
10 grams of the sample were cut out from the center of the collected liver tissue and transferred to 
a petri dish containing PBS with 1% penicillin/streptomycin. The tissue was finely minced with 
scissors and washed a couple of times with PBS. The minced sample was transferred to a flask 
containing 100 ml of cold collagenase solution (Collagenase II, 300 units/mg, 500 ng/ml in HBSS-
HEPES buffer) and softly stirred for about 10 minutes. At the end of incubation, 10 ml of FBS and 
50 ml of ice cold HBSS were added. The suspension was filtered through a nylon cell strainer (100 
micron pore size) and the filtrate was centrifuged at 50 g for 5 minutes at 4ºC. The supernatant 
was discarded and the pellet washed twice with PBS with 1% penicillin/streptomycin and 
centrifuged twice at 150 g for 2 minutes each and the pellet suspended in 5 ml PBS. The cell 
suspension was layered over 15 ml cushion of 60% Percoll in PBS in a 50 ml polycarbonate tube 
and centrifuged at 70 g at 4ºC for 5 minutes. The supernatant was discarded and the pellet washed 
with PBS. Cell viability was determined by Trypan blue dye exclusion test. The cells were 
suspended in DMEM (supplemented with 10% FBS and 1% penicillin/streptomycin) at a density 
of 0.6 million/ml and were incubated at 37ºC for 48 hours to acclimatize and form a monolayer. 
After 48 hours the media was replaced by hepatocyte maintenance media (Triangle research Labs, 
NC). No additional FBS or penicillin/streptomycin was added to the commercially purchased 
hepatocyte maintenance media. The maintenance media was changed every day. 
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Sample preparation  
 
About 106 cells were used per sample. The cells were exposed to fresh media (hepatocyte 
maintenance media for the canine hepatocytes and DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin for the canine cell lines 17-71 and GL-1) containing varying 
concentrations of lomustine, trans-4 or cis-4 metabolites (300, 1000, 3000, 10,000 and 50,000 
ng/ml) for 4 hours. This time point was based on a published study that looked at DNA alkylation 
products after exposure to lomustine and adducts were measured between 1 and 6 hours. The 
results showed that the adducts were formed rapidly and were detected at 1 hour after drug 
exposure (Bodell, 2009). In our initial experimentation, the 1 hour samples showed very low 
adduct level and hence we chose to detect the adducts at 4 hours. At the end of 4 hours, the DNA 
was isolated using Qiagen blood mini kit (Qiagen). The extracted DNA was lyophilized and 
concentrated to 100 µg. The DNA was enzymatically digested by a method described by Singer et 
al (Singer et al., 1978). The DNA sample digestion was carried out as follows: per 50 μl DNA, 10 
μl of 0.5 M Tris (pH 7.3), 2 μl of 1 M MgCl2, 10 μl DNAse I (5 mg/ml, 2303 units/mg, 
Worthington), 10 μl of snake venom phosphatase (5 mg/ml, 36 units/mg, Worthington) and 4 μl 
of bacterial alkaline phosphatase (5 mg/ml, 35 units/mg, Worthington) was added and final volume 
adjusted to 150 μl with deionized water. The mixture was incubated overnight at 37ºC and then 
heated to 100ºC for 90 seconds to inactivate the enzymes. The samples were briefly centrifuged to 
sediment the proteins. The supernatant was collected and analyzed by LC/MS/MS.  
 
Preliminary experiments showed that N7 adduct was detected at the concentration of 10,000 
ng/ml and above while the mutagenic adduct O6 hydroxyethyldeoxyguanosine was only detected 
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at 50,000 ng/ml drug concentration. Hence 10,000 ng/ml and 50,000 ng/ml concentrations were 
used to compare the adducts formed by the three drugs. For the cell lines, the experiment was done 
two separate times, with two technical replicates each. For the canine hepatocytes, the experiment 
was done once with duplicate samples.  
 
LC/MS/MS method for detection of DNA adducts 
 
An LC/MS/MS method was developed to quantify the O6 hydroxyethyldeoxyguanosine 
and N7 hydroxyethylguanine adducts in the DNA samples. 
 
Standards preparation 
 
Pure standards of O6 hydroxyethyldeoxyguanosine and N7 hydroxyethylguanine were 
purchased from Toronto research company (Toronto, Canada). Deuterated O6 methylguanine (D3-
O6 methylguanine) was used as internal standard (Sigma Aldrich). Standards were dissolved in 
methanol to prepare stock solutions. Standard curve range was 0.1-10 ng for each compound and 
50 ng of internal standard was added to each sample. The final volume was adjusted to 150 µl with 
water. 
 
LC/MS/MS conditions 
 
Samples were analyzed with the QTRAP 5500 LC/MS/MS system (AB Sciex, Foster City, 
CA) with the 1200series HPLC system (Agilent Technologies, Santa Clara, CA) including a 
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degasser, an autosampler, and a binary pump.  The LC separation was performed on an Agilent 
SB-Aq column (4.6 mm × 50 mm, 5µ) (Santa Clara, CA) with mobile phase A (0.1% formic acid 
in water) and mobile phase B (0.1% formic acid in acetonitrile).  The flow-rate was 0.35 
ml/min.  The linear gradient was as follows: 0-1 min, 100% A; 8-11 min, 25% A; 12-18 min, 100% 
A. 
   
The autosampler was set at 5ºC and the injection volume is 5 µL.  Positive mass 
spectrometry was achieved with electrospray ionization (ESI). The ion spray voltage was 5500 
V.  The source temperature was 400 ºC. The curtain gas, ion source gas 1, and ion source gas 2 
were 32, 65, and 50, respectively.  Multiple reaction monitoring (MRM) was used to quantify O6- 
hydroxyethyldeoxyguanosine (m/z 312.2 à m/z 110.1),  N7-hydroxyethylguanine (m/z 196.1 à m/z 
110.1), and the internal standard deuterated O6-methylguanine (m/z 169.1 à m/z 70.1) (Figure 4.1). 
 
Carbamylation assay 
 
Carbamylation was measured in primary hepatocytes harvested from six dogs euthanized 
at the Champaign county animal control facility (hepatocyte isolation procedure as mentioned 
above) and canine cell lines 17-71 and GL-1 after treatment with lomustine and its metabolites 
using Oxyselect™ carbamylation ELISA kit. The quantity of carbamylated lysine (CBL) in protein 
samples is determined by comparing its absorbance with that of a known CBL-BSA standard 
curve. 
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About 106 cells were used per sample. The cells were exposed to fresh media (hepatocyte 
maintenance media for the canine hepatocytes and DMEM supplemented with 10% FBS and 1% 
penicillin/spreptomycin for the canine cell lines 17-71 and GL-1) containing varying 
concentrations of lomustine, trans-4 or cis-4 metabolites (300, 1000, 3000 and 10,000 ng/ml). 
Carbamylation was measured at 4 hours after exposure to drugs as per the ELISA kit instructions. 
Carbamylation is a rapid process occurring within a few minutes and previously published studies 
have measured carbamylation at similar time points (Heal et al., 1978; Wheeler et al., 1974). Initial 
experimentation did not show any carbamylation at 300, 1000 and 3000 ng/ml drug concentration. 
Thus 10,000 ng/ml concentration was used to compare the carbamylation effects of the three drugs. 
For the cell lines, the experiment was done two separate times, with two technical replicates each. 
For the canine hepatocytes, the experiment was done once with duplicate samples. 
 
Statistical analysis 
 
Statistical analysis was done using SPSS (IBM, NY). Descriptive statistics were produced 
for all continuous variables. Mean and standard deviation were calculated.  Normality of data was 
assessed using the Shapiro-Wilks test.  Paired t-tests were performed to evaluate differences 
between technical repeats of each drug. One way ANOVA and Tukey’s post hoc test were 
performed to evaluate the between drug differences. The p value was set at 0.05. 
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4.3 Results 
 
There is no significant difference in the levels of adducts formed by lomustine, trans-4 or 
cis-4. This can be correlated with the similar cytotoxicity observed in the cells after treatment with 
the three compounds. The N7 hydroxyethylguanine adduct was detected at similar level in 17-71, 
GL-1 and the hepatocytes from 6 dogs after exposure to lomustine, trans-4 and cis-4 at 10,000 
ng/ml and 50,000 ng/ml concentration (Figure 4.2). However the mutagenic adduct O6 
hydroxyethyldeoxyguanosine was detected at a significantly lower level (2-3 fold) in the 
hepatocytes as compared to the cell lines when treated with the three drugs at 50,000 ng/ml 
concentration (Figure 4.3).  
 
In the canine cell lines 17-71 and GL-1 and in the canine hepatocyte samples, lomustine 
caused significantly greater carbamylation (about 1.5 fold) as compared to its metabolites (Figure 
4.4). Both the metabolites showed similar carbamylation levels. In all the six canine hepatocyte 
samples tested, the carbamylation caused by all the three drugs was 1.5-2 fold greater than that 
seen in 17-71 and GL-1 cells. Among the six dog hepatocyte samples, two dogs showed about 2 
fold higher level of carbamylation compared to the others with lomustine, trans-4 and cis-4).  
 
4.4 Discussion 
 
In our study we found that there is no significant difference in the N7 hydroxyethylguanine 
and O6 hydroxyethyldeoxyguanosine adduct level formed by lomustine, trans-4 and cis-4 which 
correlates with the similar cytotoxicity of these compounds. The mutagenic O6 adduct was higher 
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in the canine cell lines 17-71 and GL-1 as compared to the hepatocytes which may indicate either 
lower adduct formation or rapid repair. Rapid repair may be a possibility since all the canine 
hepatocyte samples showed greater MGMT level (elaborated in chapter 5). It can be speculated 
that as MGMT is a DNA repair enzyme, an enhanced repair of O6 adducts could contribute to the 
reduced sensitivity of hepatocytes to the alkylating action of lomustine and its metabolites. 
 
It should however be noted that we have only detected the levels of two individual adducts 
after drug exposure. The cell killing action of nitrosoureas may be orchestrated by the formation 
and cumulative action of multiple adducts that these drugs are capable of forming. Also, in case of 
chloroethylating agents like lomustine, cross linking of DNA is known to be harmful lesion that 
can lead to double stand breaks and ultimately apoptosis (Lemoine et al., 1991). This cross linking 
of DNA is initiated by the formation of O6 chloroethyldeoxyguanosine adduct. This adduct is 
highly unstable and cross links with the cytosine on the opposite stand forming the cytotoxic cross 
links (Lemoine et al., 1991; Ludlum, 1990). Thus in our alkylation study, measuring the two 
adducts can act only as a molecular dosimeter of therapeutic response and not a measure of the full 
extent of alkylation caused by the drugs.  
 
Carbamylation was measured in the canine lymphoma cell lines and hepatocytes by an 
ELISA kit. The assay measures the amount of carbamylated lysine (CBL) in the samples. Our 
results show that lomustine causes greater carbamylation as compared to its metabolites in canine 
cell lines and hepatocytes. All the three compounds caused greater carbamylation in hepatocytes 
as compared to the canine cell lines. Also hepatocyte samples from two dogs showed greater 
carbamylation following treatment with lomustine and its metabolites compared to the others. But 
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it should be noted that all of the dog hepatocyte samples showed no cytotoxicity to lomustine or 
its metabolites up to six days of incubation (elaborated in chapter 3). Hence it is unlikely that 
greater carbamylation in the hepatocytes in the two dogs would lead to cell death in our 
experiments, although it may be inhibiting various proteins in these cells. The same would also 
hold true for the cell lines 17-71 and GL-1 where we see lower carbamylation but greater 
cytotoxicity after treatment with the drugs.  
 
Even though the hepatocyte samples showed greater carbamylation than the cell lines it is 
not known if this is of clinical relevance with regards to hepatotoxicity caused by lomustine since 
carbamylation levels have not been measured in dogs that show hepatotoxicity after lomustine 
treatment. There is no clear correlation between the carbamylating potential of the isocyanates 
formed from nitrosourea and the cytotoxicity as nitrosoureas that have low carbamylating activity 
retain their antitumor activity (Lemoine et al., 1991). However carbamylation of proteins may 
interfere with the proper functioning or replication of the cells which may not necessarily result in 
cell death.  It has also been shown that nitrosoureas which form isocyanates are particularly able 
to inhibit the polymerization of purified brain tubulin in a dose dependent manner (Brodie et al., 
1980). In a study where rats were given lomustine by oral gavage at 50 mg/kg dose, and sacrificed 
at different time points, the hepatocytes remained normal at early time points although the bile 
canaliculi became dilated and contained bile thrombi (Kretschmer et al, 1987). In another study in 
rats that were administered lomustine at 20 mg/kg, hepatocytes were not markedly altered with 
normal nuclei and cell organelles. The main alteration of the parenchymal cells occurred after the 
6th day with modification of the cytoskeletal components and reduction in number of microtubules 
(Ducastelle et al., 1988). It is suggested that the isocyanates carbamylate tubulin in hepatocytes 
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leading to mitotic spindle inhibition and G2 cell cycle arrest or may cause disruption of secretory 
functions such as bile secretion which in turn results in cholestasis and secondary hepatic injury 
(Ducastelle et al., 1988; Laquerriere et al., 1991). Thus carbamylation of proteins may not 
necessarily manifest as immediate cell killing. 
 
In this study we have shown that lomusine and its metabolites form similar levels of the 
DNA adduct N7 hydroxyethylguanine and O6 hydroxyethyldeoxyguanosine which corresponds to 
the similar cytotoxicity of these compounds. In terms of carbamylation, lomustine showed greater 
carbamylation in the canine hepatocytes and lymphoma cell lines. Thus if carbamylation of 
proteins is indeed one of the reasons for the side effects of lomustine, then using the metabolites 
instead may be a better option in terms of side effects. 
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4.5 Figures and Legends 
Figure 4.1 LC/MS/MS Multiple Reaction Monitoring (MRM) analysis for O6 
hydroxyethyldeoxyguanosine, N7 hydroxyethylguanine and D3-O6 methylguanine 
 
 
 
 
 
 
 
 
 
 
 
D3- O6 methylguanine – internal standard 
O6 hydroxyethyldeoxyguanosine 
N7 hydroxyethylguanine 
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Figure 4.2 Graphs showing the N7 hydroxyethylguanine adduct formed after treatment with 
lomustine, trans-4-hydroxylomustine and cis-4-hydroxylomustine metabolites at 10,000 ng/ml (A)  
and 50,000 ng/ml (B) concentration in 17-71 and GL-1 cells and  hepatocytes from 6 dogs (n=6).  
No statistically significant difference was seen in the N7 hydroxyethylguanine levels in 17-71 and 
GL-1 cells and canine hepatocytes with lomustine, trans-4-hydroxylomustine and cis-4-
hydroxylomustine. 
 
 
 
 
 
 
  
 
 
 
(A) 
(B) 
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Figure 4.3 Graph showing the O6 hydroxyethyldeoxyguanosine adduct formed after treatment 
with lomustine, trans-4-hydroxylomustine and cis-4-hydroxylomustine metabolites at 50,000 
ng/ml concentration in 17-71 and GL-1 cells and  hepatocytes from 6 dogs (n=6). No statistically 
significant difference was seen in the O6 hydroxyethyldeoxyguanosine levels formed by lomustine, 
trans-4-hydroxylomustine and cis-4-hydroxylomustine in the same cell type.* denotes statistical 
significance as compared to the 17-71 and GL-1 cells. p=0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* * 
* 
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Figure 4.4 Graphs showing the carbamylation induced by lomustine, trans-4-hydroxylomustine 
and cis-4-hydroxylomustine at 10,000 ng/ml concentration in 17-71 and GL-1 cells (A) and 
hepatocytes from 6 dogs (B). The data represents the mean and standard deviation. * indicates 
statistical significance compared to trans-4-hydroxylomustine and cis-4-hydroxylomustine. 
p=0.05 
 
 
 
 
 
 
 
 
 
(A) 
* * 
* 
* * * 
* 
* 
(B) 
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CHAPTER V 
 
MGMT mRNA expression and enzyme activity in canine lymphoma cell lines and 
hepatocytes 
 
5.1 Introduction 
 
The DNA protective enzyme O6-methylguanine-DNA methyltransferase (MGMT) is 
known to play a critical role in the defense against alkylating compounds which produce the O6 
alkylguanine lesion. This defense is thought to be crucial at the cellular level as there are many 
environmental carcinogens that also act as alkylating agents (Kaina et al., 2007). MGMT is not 
essential for life as MGMT knockout mice are viable and phenotypically normal, however they 
are hypersensitive to cell killing by alkylating agents (Kaina et al., 2007). Mice that were 
engineered to be deficient in MGMT, when administered methylnitrosourea (MNU) died early as 
compared to the wild type and also showed greater frequency of tumor formation (Chaney & 
Sancar, 1996; Sakumi et al., 1997).  
 
Unlike other DNA repair mechanisms such as, base excision repair or nucleotide excision 
repair, MGMT is unique in that it can repair the DNA without the help of other enzymes or 
cofactors. Repair of the O6 alkylguanine adduct via MGMT is a rapid single step process in which 
the offending alkyl group is transferred to the cysteine residue of MGMT thereby restoring the 
affected DNA (Gerson, 2002; Kaina et al., 2007; Sedgwick, 2004). The reaction is stoichiometric 
in nature where one MGMT molecule removes a single DNA adduct. Once used, the MGMT 
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molecule cannot be recycled and is directed towards ubiquitination (Gerson, 2002; Srivenugopal 
et al., 1996) and degraded by the proteasome (Xu-Welliver & Pegg, 2002). Therefore a cell’s 
capacity to repair the O6 adducts on the DNA depends on the number of MGMT molecules already 
present and also the rate of de novo synthesis (Kaina et al., 2007). 
 
The MGMT level is highly variable among individuals and also among the various tissues 
in the same individual (Christmann et al., 2011). A long term study of MGMT in PBMC from 
healthy human subjects showed that there is a 7 fold variation in MGMT activity with very little 
change over time (Janssen et al., 2001). Data from human studies have shown that liver has the 
highest MGMT activity, while the brain has the lowest (Christmann et al., 2011). Also the MGMT 
activity varies between normal and malignant tissues. However it is unclear if MGMT activity 
changes during carcinogenesis (Christmann et al., 2011). 
 
Due to its functional role in DNA repair, MGMT may have a significant impact on the 
outcome of cancer therapy with alkylating agents. Certain tumors that are high expressers of 
MGMT were found to be less sensitive to treatment with nitrosoureas while tumors that were 
deficient in MGMT or showed relatively low expression responded better to nitrosourea therapy 
(Christmann et al., 2011). MGMT levels in normal tissues may also have significant impact on the 
choice of therapy to be used. A dose limiting side effect of most nitrosourea compound is 
myelotoxicity, and it is thought that this could be due to the low MGMT expression in bone marrow 
cells (Gerson, 2002; Maze et al., 1996). There is data indicating that MGMT expression is 
inducible (via transcriptional activation) by alkylating agents, X-ray or other DNA damaging 
agents (Grombacher & Kaina, 1995). Studies in rat liver cells have shown a 2-5 fold MGMT gene 
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induction with maximum induction happening around 24 to 48 hours after exposure to X-ray or 
alkylating agent, methylnitronitrosoguanidine (MNNG) (Grombacher et al., 1996; Grombacher & 
Kaina, 1995).  
 
In this study, we evaluated the MGMT expression and enzyme activity in canine lymphoma 
cell lines and primary canine hepatocytes. There is no published data available regarding the 
MGMT level in canine cells and tissues. Also, we tried to correlate the MGMT levels with the 
cytotoxicity of lomustine and its metabolites in these cells and also the level of DNA adducts 
formed by these compounds. 
 
5.2 Materials and Methods 
 
MGMT mRNA expression in 17-71 and GL-1 cells and canine primary hepatocytes 
 
The lymphoma cell lines 17-71 and GL-1 were grown and maintained at 37°C in 5% CO2, 
and cultures were passaged as necessary to maintain high cell viability (above 90%) in culture 
media DMEM supplemented with 10% FBS, 1% penicillin/streptomycin. For the MGMT gene 
induction study, MGMT gene expression was measured in canine lymphoma cell lines 17-71 and 
GL-1 at 6, 12, 24 and 48 hours after exposure to varying concentrations of lomustine (1000, 3000 
and 12,000 ng/ml) to study MGMT induction. The cells were only treated with 12,000 ng/ml 
concentration of trans-4 and cis-4, based on the initial results obtained after lomustine treatment 
study. Untreated samples were used to measure basal MGMT mRNA expression in these cells.  
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Isolation of canine hepatocytes 
 
Hepatocytes were isolated from six dogs that were euthanized at the Champaign county 
animal control facility. Isolation of canine hepatocytes was done by the by the method of  Spotorno 
et al. (Spotorno et al., 2006) with few modifications. Liver samples (about 25 grams) from freshly 
euthanized dogs were obtained aseptically and immediately transported in PBS to the lab. About 
10 grams of the sample were cut out from the center of the collected liver tissue and transferred to 
a petri dish containing PBS with 1% penicillin/streptomycin. The tissue was finely minced with 
scissors and washed a couple of times with PBS. The minced sample was transferred to a flask 
containing 100 ml of cold collagenase solution (Collagenase II, 300 units/mg, 500 ng/ml in HBSS-
HEPES buffer) and softly stirred for about 10 minutes. At the end of incubation, 10 ml of FBS and 
50 ml of ice cold HBSS were added. The suspension was filtered through a nylon cell strainer (100 
micron pore size) and the filtrate was centrifuged at 50 g for 5 minutes at 4ºC. The supernatant 
was discarded and the pellet washed twice with PBS with 1% penicillin/streptomycin and 
centrifuged twice at 150 g for 2 minutes each and the pellet suspended in 5 ml PBS. The cell 
suspension was layered over 15 ml cushion of 60% Percoll in PBS in a 50 ml polycarbonate tube 
and centrifuged at 70 g at 4ºC for 5 minutes. The supernatant was discarded and the pellet washed 
with PBS. Cell viability was determined by Trypan blue dye exclusion test. The cells were 
suspended in DMEM (supplemented with 10% FBS and 1% penicillin/streptomycin) at a density 
of 0.6 million/ml and were incubated at 37ºC for 48 hours to acclimatize and form a monolayer. 
After 48 hours the media was replaced by hepatocyte maintenance media (Triangle research Labs, 
NC) without FBS or penicillin/streptomycin. 
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MGMT mRNA expression assay 
 
The total RNA from samples was extracted using RNeasy mini kit (Qiagen). Relative 
expression levels of the MGMT gene was carried out using Taqman Real-Time quantitative RT-
PCR (QPCR) analysis on an ABI Prism 7500 thermal cycler. An ABI canine MGMT specific 
Taqman probe (cf02626419_m1) spanning the exon 1/2 junction was used for all analyses. HPRT-
1 was used as internal reference for normalization (ABI Taqman probe cf02626258_m1). For this 
analysis, 1 µg aliquot of total RNA from a given sample was converted to cDNA using Superscript 
III first strand synthesis system (Life technologies). The resulting cDNA was used in separate 
Taqman QPCR analyses, each including triplicate technical repeats. Expression comparisons was 
made between treated and untreated (control) samples and also between different cell types. The 
mRNA expression was measured two separate times in all samples (canine cell lines and 
hepatocytes). In order to ascertain that the Taqman assay is able to detect the gene expression 
correctly, MGMT gene expression was measured in three canine glioma cell lines J3T-Bg, SDT-
3 and G06A (York et al., 2011).  
 
MGMT enzyme activity in 17-71 and GL-1 cells and canine hepatocytes 
 
A fluorometric oligonucleotide assay was used for measuring MGMT enzyme activity 
(Kreklau et al., 2001). The following 18 base pair (bp) 5’hexachlorofluoroscein phosphoramitide 
(HEX) labelled oligonucleaotide (oligo) containing O6-methylguanine lesion within a PvuII 
restriction site and its complementary oligo were custom made (Sigma Aldrich).  
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  Hex labeled oligo:        5’HEX-GCCCGGCCAGCTGCAGTT 
  Complementary oligo:          3’-CGGGCCGGTCGACGTCAA 
  
 G = O6 methylguanine 
 
Oligonucleotide strands were annealed to complementary strands in 10 mM Tris–HCl, 1 mM 
EDTA, 33 mM NaCl, pH 8.0, by heating to 90°C for 2 minutes to denature and cooling to room 
temperature overnight. The 17-71 and GL-1 cells and hepatocytes were maintained in culture 
media as mentioned above. Cells (106) were harvested and resuspended in serum-containing 
culture medium (DMEM), then centrifuged at 1500 g for 5 minutes.  
 
The cells were washed with 5–10 ml of PBS and recentrifuged, then resuspended in 0.5 ml 
assay buffer (50 mM Tris–HCl, 1 mM DTT, 0.5 mM EDTA, 5% glycerol, pH 8.0) and kept on ice. 
Protein from cells (about 106 cells/sample) was extracted by pulse-sonication on ice five times for 
5 seconds each, then centrifuged at 14,000 g at 4°C for 30 minutes. The total protein was 
quantitated by measuring absorbance at 595 nm using the Pierce BCA kit reagent. To measure the 
MGMT activity the 200 fmols of HEX labeled oligo was incubated with cell protein (500 µg) at 
37°C for 2 hours. The oligo was extracted by phenol:chloroform:isoamyl alcohol (25:24:1) 
extraction and using sodium acetate and ethanol with tRNA (10 µg) as a carrier. Equal volume of 
phenol:chloroform:isoamyl alcohol solution was mixed with the oligo cell protein mixture along 
with 50 µl sodium acetate and 10µg tRNA.  This was vortex mixed briefly for a few seconds until 
an emulsion was formed. This mixture was centrifuged at 12,000 g for 3-5 minutes at room 
PvuII restriction site 
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temperature. The upper aqueous phase was transferred to a new tube and the interface and bottom 
organic phases were discarded. The purified oligo was digested with a restriction enzyme PvuII 
(Promega) for 2 hours in a total reaction mixture of 20 µl following manufacturer’s instructions. 
PvuII cleaves the oligo at the O6-methylguanine lesion producing two short fragments (10 bp and 
8 bp). Then formamide loading buffer (10 µl), without dyes was added to each sample and the 
samples were denatured by heating at 95°C for 5 minutes. Sample solutions (15 µl) were applied 
to a pre-warmed 20% polyacrylamide gel containing 8 M urea in 1× Tris–borate EDTA (TBE) 
buffer and run at 50 mA for 15 minutes. Detection and quantitation of the fluorescent HEX labeled 
oligonucleotides was done by using a fluorescent imaging system (Typhoon 9410 Variable Mode 
Imager).  
 
The MGMT enzyme activity was quantified by comparing the intensity of the bands (18 
bp) between the PvuII treated and PvuII nontreated (control) samples. The MGMT activity was 
calculated by comparing the intensity (density volume obtained from the fluorescent reader) of the 
top band (18 bp) in the samples with that in the controls. The deficit in intensity in the sample 
bands compared to the control bands represents the amount of cleavage which corresponds to the 
MGMT enzyme activity. For the cell lines and hepatocytes, the experiment was done with 
duplicate samples. 
 
For measuring the lower limit of detection (LOD) and limit of quantitation (LOQ) of the 
method, serial dilution of the HEX labelled oligo was made from 1-200 fmols in deionized water 
and the fluorescent intensity was measured and this was plotted against the oligo concentration. 
The lowest concentration showing 3 times the fluorescent intensity compared to the blank sample 
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was chosen as the LOD and the lowest concentration with CV less than or equal to 15% was chosen 
as the LOQ of the method.   
 
Statistical analysis 
 
Statistical analysis was done using SPSS (IBM, NY). Descriptive statistics were produced 
for all continuous variables. Mean and standard deviation were calculated. Kruskal-Wallis one 
way ANOVA was used to compare the means of the drug treated and non-treated groups at 
different time points in the MGMT gene induction study. Correlation between MGMT mRNA 
expression and enzyme activity was evaluated by Pearson’s correlation. The p value was set at 
0.05. 
 
5.3 Results 
 
MGMT gene expression 
 
GL-1 cells did not show any MGMT mRNA expression in untreated samples. When GL-1 
samples were treated with lomustine, trans-4 and cis-4 at 1000, 3000 and 12,000 ng/ml and 
incubated for 12, 24 and 48 hours, still no MGMT mRNA expression was detected. In the 17-71 
cells, a low basal level of MGMT expression was seen in the untreated samples (Figure 5.1). Upon 
treatment with various concentrations of lomustine, trans-4 and cis-4 and incubated for different 
time points, no statistically significant difference was seen in any of the drug treated samples at 
any time point as compared to the vehicle control (Figures 5.1 and 5.2). Two of the glioma cell 
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lines SDT-3 and J3G-Bg showed high MGMT mRNA expression (Figure 5.3). The results show 
that the Taqman qPCR assay is able to detect higher transcript levels of MGMT gene and that the 
previously measured low MGMT gene expressions in 17-71 cells are indeed true values. 
 
The MGMT gene expression measured in the hepatocytes of the 6 dogs was 2-3 fold greater 
than that seen in the 17-71 cells (Figure 5.4). The variation in MGMT mRNA expression among 
the 6 dogs was low except for one dog which showed a lower MGMT level. 
 
MGMT enzyme activity 
 
The LOD of the fluorometric MGMT enzyme activity assay was 5 fmols while the LOQ 
was 10 fmols (Figure 5.5). For GL-1 and 17-71 cell line, using 100 µg and 200 µg of cell protein 
did not show any MGMT activity. In order to ascertain the functionality of the assay, human 
recombinant MGMT (Cayman chemicals) was used as a positive control. The results showed that 
with increasing concentration of MGMT, greater cleavage of the oligo was seen (Figure 5.6). Thus 
the protein amount in the assay was increased to 500 µg and in the 17-71 samples showed visible 
cleavage of the oligo (Figure 5.7). The GL-1 cell lines did not show any MGMT enzyme activity 
even when 500 µg cell protein was used for the assay.  
 
The MGMT activity in the 17-71 cells was about 90 fmols/mg protein (range 83-96 
fmols/mg protein, SD 10.11). In the GL-1 cell line, as no MGMT gene expression was detected, 
consequently, MGMT enzyme activity was also absent. The enzyme activity measured in the 
hepatocytes was greater than in 17-71 cells, proportional to the mRNA levels. The MGMT enzyme 
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activity measured in canine hepatocytes is about 250-350 fmols/mg protein (Figures 5.8 and 5.9). 
There was good correlation between MGMT gene expression and enzyme activity in the 17-71 
and the canine hepatocytes (Figure 5.10).  
 
5.4 Discussion 
 
This data is of significance as there is no prior published report of the MGMT gene 
expression or enzyme levels in canine cells or tissues. The canine lymphoma cell line 17-71 
showed low MGMT mRNA expression and enzyme activity (about 90 fmols/mg protein). MGMT 
activity data from humans show that similar level of activity is seen in brain tissue (about 100 
fmols/mg protein) which is one of the organs expressing the lowest level of MGMT activity in the 
body (Christmann et al., 2011). This may be one of the reasons for the higher success rate of 
nitrosourea therapy on brain tumors (Christmann et al., 2011). The GL-1 cells did not show any 
detectable MGMT mRNA expression or enzyme activity. It has been reported that while MGMT 
is expressed in all normal human cell types and tissues, 20- 30% of human tumor or more than 
50% of virally transformed cell lines are completely deficient in MGMT expression (Day et al., 
1980; Tsujimura et al., 1987). It is not clear yet if the process of immortalization may be leading 
to loss of MGMT expression (Harris et al., 1996). The mechanism of suppression of the MGMT 
gene in MGMT negative cells is not yet understood. However, it is known that lack of expression 
is not due to deletion of the gene (Tano et al., 1990) and may possibly be an epigenetic event 
(Cairnssmith & Karran, 1992; Vonwronski & Brent, 1994). 
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MGMT induction is known to result from transcriptional activation of the MGMT gene in 
response to DNA damage (Grombacher et al., 1998). In our gene induction study, the 17-71 cells 
did not show any significant increase in gene expression after 48 hours of exposure to lomustine 
and its metabolites. The experiment was only done twice and the percent SD between samples 
from the two experiment was 7- 35% which probably led to the non-significant values. Time 
dependent expression of MGMT gene has been measured after exposure to different types of DNA 
damages including X-ray treatment and methylating agents, and the maximum induction (2-5 fold) 
was seen at 24 to 72 hours (Grombacher et al., 1996). Also the half-life of MGMT mRNA is known 
to be over 10-12 hours and that for the protein is over 15-20 hours (Kroes & Erickson, 1995; Pegg, 
1977).  
 
The hepatocytes obtained from the six dogs showed a 2-3 fold greater MGMT mRNA 
expression as compared to the canine cell line 17-71. The MGMT enzyme activity measured in 
the hepatocytes is about 250-350 fmol/mg protein as compared to 90 fmol/mg protein in 17-71 
cells. This indicates a positive correlation between the MGMT mRNA expression and the enzyme 
activity in the canine cell lines and the hepatocytes. Data from humans also suggest that MGMT 
activity corresponds with the MGMT protein and RNA level (Christmann et al., 2011). The 
average MGMT activity in human liver is reported to be around 600 fmol/mg protein, however 
there is wide inter-individual variation (Christmann et al., 2011; Margison et al., 2003). In our 
MGMT activity assay in hepatocytes, there was over 70% enzymatic cleavage of the substrate 
oligo (Figure 5.7). This may indicate a sub-optimal enzyme-substrate ratio which could lead to a 
lower rate of reaction. It is suggested that enzyme reactions be conducted under initial rate 
conditions with total consumption of substrate less than 20% (Wenham et al. 2006). Hence it is 
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possible that the MGMT activity measured in the canine hepatocytes in our study is lower than the 
actual values. 
 
In chapter 3 we have seen that lomustine and its metabolites showed a time and 
concentration dependent toxicity in canine lymphoma cell lines 17-71 and GL-1. However the 
canine hepatocytes did not show any detectable cell killing even 6 days after exposure to the drugs. 
When the toxic O6 guanine adduct was measured in the cells after exposure to lomustine and the 
metabolites, the canine cell lines showed higher levels of the adduct as compared to the 
hepatocytes. It is known that MGMT directly repairs the O6 adducts in a rapid stoichiometric 
reaction. In our MGMT study we saw that the hepatocytes had 2-3 fold greater enzyme activity 
compared to the 17-71 cell line. Correlating all this data together it is plausible that higher MGMT 
enzyme activity may be a reason for the lower levels of O6 adducts detected in the hepatocyte 
samples. The higher level of MGMT may cause repair of adducts, and hence contributing to the 
lower cytotoxicity of lomustine and its metabolites in hepatocytes. However this interpretation 
must be viewed with caution, as no significant difference in the O6 adduct levels between 17-71 
cells and GL-1 cells was noted even though we were unable to detect any MGMT activity in the 
GL-1 cells. Also lomustine and its metabolites form multiple adducts at the O6 guanine position 
out of which we chose the O6 hydroxyethyldeoxyguanosine as a marker or indicator of the 
genotoxic potential of the compounds. It should be noted that MGMT is only one of the several 
ways in which alkylation damage in DNA is repaired by the cell. Other pathways such as base 
excision repair and mismatch repair are also known to repair damaged DNA depending on the 
stage and type of the damage. Thus it may also be possible that the lower O6 
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hydroxyethyldeoxyguanosine measured in the hepatocytes may be due to lower formation or a 
DNA repair mechanism other than MGMT. 
 
In summary, we showed that MGMT mRNA expression in 17-71 cells and canine 
hepatocytes correlates with the MGMT enzyme activity in these cells. There was low MGMT 
activity in the canine lymphoma cell line 17-71 while the GL-1 cells did not show any detectable 
enzyme activity or mRNA expression. The canine hepatocytes have greater MGMT activity as 
compared to the 17-71 cell line. 
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5.5 Figures and Legends 
Figure 5.1 Graph showing MGMT mRNA expression in 17-71 cells before (untreated) and after 
treatment with lomustine at 1000, 3000 and 10,000 ng/ml and incubated for 6, 12, 24 and 48 hours. 
No statistical significance was seen in MGMT mRNA expression in any of the drug treated 
samples at any time point as compared to the untreated samples. 
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Figure 5.2 Graph showing MGMT mRNA expression in 17-71 cells before (untreated) and after 
treatment with trans-4-hydroxylomustine and cis-4 hydroxylomustine at 12,000 ng/ml 
concentration and incubated for 6, 12, 24 and 48 hours. No statistical significance was seen in 
MGMT mRNA expression in any of the drug treated samples at any time point as compared to the 
untreated samples. 
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Figure 5.3 Graph showing MGMT mRNA expression in canine glioma cell lines J3T-Bg, SDT-3 
and G06A and canine lymphoma cell line 17-71. 
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Figure 5.4 Graphs showing the MGMT mRNA expression in canine lymphoma cell line 17-71 
cells and primary hepatocytes from 6 dogs.  
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Figure 5.5 Serially diluted oligo from 1-200 fmols to detect LOD and LOQ of the method. Amount 
of oligo in each lane is as follows: Lane 1=1 fmol, lane 2=5 fmols, lane 3=10 fmols, lane 4=20 
fmols, lane 5=50 fmols, lane 6=100 fmols, lane 7=150 fmols and lane 8=200 fmols.  
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Figure 5.6 Oligo treated with increasing concentration of human recombinant MGMT. Lane 1 
represents untreated oligo. Oligos in lane 2-7 were treated with MGMT at 5, 10, 20, 50, 100 and 
200 ng/ml concentration. Upper and lower bands represent 18 bp substrate and 10 bp cleavage 
product, respectively. 
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Figure 5.7 MGMT activity in canine lymphoma cell line 17-71: lanes 1-3 represent replicate oligo 
samples treated with 500 μg cell protein from 17-71 cells. Lanes labeled ‘N’ are untreated oligo 
samples (control). Upper and lower bands represent 18 bp substrate and 10 bp cleavage product, 
respectively.  
 
 
 
 
 
 
  
N N 1 2 3 
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Figure 5.8 MGMT activity in primary hepatocytes obtained from 6 dogs: lanes 1-6 represent oligo 
samples treated with 500 μg cell protein from hepatocytes obtained from 6 dogs. Lanes labeled 
‘N’ are untreated oligo samples (control). Upper and lower bands represent 18 bp substrate and 10 
bp cleavage product, respectively.  
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Figure 5.9 Graph showing MGMT enzyme activity in the primary hepatocytes obtained from 6 
dogs and in the canine lymphoma cell line 17-71. 
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Figure 5.10 Graph showing correlation between MGMT gene expression and enzyme activity in 
canine lymphoma cell line 17-71 and the hepatocytes obtained from 6 dogs. Pearson’s correlation 
was 0.806 which is highly significant with p value of 0.028. (p value set at 0.05). 
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CHAPTER VI 
Conclusion 
 
6.1 Conclusion 
 
The primary goal of this project was to study the metabolism of lomustine in dogs and to 
compare the cytotoxicity of lomustine and its trans-4 and cis-4 metabolites, as these metabolites 
have shown better therapeutic index compared to the parent drug in human patients (Wheeler et 
al., 1977). Another goal was to measure the level of the DNA protective enzyme MGMT in canine 
cells, which is thought to play a role in the cytotoxicity of lomustine.  
 
Chapter 2 discussed the stability and metabolism study of lomustine in dogs. From the 
stability study we can conclude that lomustine, trans-4 and cis-4 are relatively stable in methanol 
but labile in canine plasma. Thus, unknown canine samples following administration of lomustine 
should be stored at -80oC and analyzed within a week for better accuracy when determining the 
pharmacokinetic parameters of lomustine in dogs. The results of the metabolism study show that 
the metabolic profile of lomustine in dogs was similar to that in humans with trans-4 being the 
major metabolite and cis-4 as the minor metabolite. Also parent lomustine was not detected in the 
blood samples from the dogs at any time after oral administration of the drug. The data obtained 
from this metabolism study may be considered as preliminary as it was carried out only in three 
dogs. Data from humans show about 5-10 fold difference between the maximum concentrations 
of trans-4 observed among patients (Kastrissios et al., 1996). This supports the premise that there is 
a large inter-individual difference in the metabolic profile of lomustine. However, based on our 
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results, we may conclude that studying the pharmacokinetics of lomustine in dogs may not yield 
substantial information that could alter therapy. Our preliminary metabolism study results indicate 
that the metabolites may be carrying out a major part of the chemotherapeutic effects of lomustine 
as only the metabolites were detected in blood after oral administration of lomustine. But due to 
their unstable nature that causes them to spontaneously breakdown at physiological body 
conditions, studying pharmacokinetics of lomustine or its metabolites may not yield any useful 
data which could be used to modify treatment protocol of lomustine. 
     
Chapter 3 elaborates the comparative cytotoxicity of lomustine and its major metabolites 
in canine lymphoma cell lines 17-71 and GL-1, PBMC from lymphoma dogs and canine primary 
hepatocytes. From this study we conclude that there is no difference in the cytotoxicity of 
lomustine, trans-4 and cis-4 in the canine lymphoma cell lines, 17-71 and GL-1. In addition to the 
concentration-dependent cell killing, all the three compounds also showed a time dependent-cell 
killing in the cell lines. Thus, exposure to higher concentration and longer incubation afterwards, 
showed greater reduction in cell viability. Interestingly, the primary cells like PBMC and 
hepatocytes did not show any sensitivity towards lomustine and its metabolites. One reason for the 
non-significant cytotoxic response in hepatocytes could be that primary cells that are non-
replicating, may require much longer time to show apparent cell killing with alkylating 
compounds. Nitrosoureas like lomustine are known to form toxic adducts on the DNA and during 
cell replication, this epigenetic modification may lead to double strand breaks which is known to 
be a potent inducer of apoptosis (Kaina, 2003; Kaina et al., 2007). This may explain why we did 
not see any cell killing in the hepatocytes even six days after lomustine treatment and also in the 
PBMC which are terminally differentiated. Evaluating the long term cytotoxic effects may show 
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that the lomustine and its metabolites cause cell killing in hepatocytes, however the time duration 
till the cytotoxicity becomes apparent, is unpredictable. In some clinical studies, it is reported that 
hepatoxicity after lomustine treatment may be delayed or cumulative in nature occurring after a 
few doses (Kristal et al., 2004).  
 
In chapter 4, we compared the alkylating and carbamylating potential of lomustine and its 
metabolites in canine lymphoma cell lines and hepatocytes. Alkylation is thought to be the reason 
for the efficacy of the drugs while carbamylation has been implicated as the cause for the side 
effects seen with lomustine treatment (Lemoine et al., 1991).  In the alkylation study we have 
shown that lomustine and its metabolites form similar levels of the DNA adducts N7 
hydroxyethylguanine and O6 hydroxyethyldeoxyguanosine. These adducts may be used as 
molecular dosimeter of therapeutic response which corresponds to the similar cytotoxicity of these 
compounds. However the mutagenic adduct O6 hydroxyethyldeoxyguanosine was detected at a 
significantly lower level (2-3 fold) in the hepatocytes as compared to the cell lines which may 
indicate either lower adduct formation or rapid repair. Rapid repair of the O6 adduct may be a 
possibility since all the canine hepatocyte samples showed greater MGMT level. 
 
In terms of carbamylation, lomustine caused greater carbamylation in the canine 
hepatocytes and lymphoma cell lines. All the three compounds caused greater carbamylation in 
hepatocytes as compared to the canine cell lines. Also hepatocyte samples from two dogs showed 
greater carbamylation following treatment with lomustine and its metabolites compared to the 
others.   But it should be noted that all of the dog hepatocyte samples showed no cytotoxicity to 
lomustine or its metabolites up to six days of incubation. Hence it is unlikely that greater 
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carbamylation in the hepatocytes in the two dogs would lead to cell death in our experiments, 
although it may be inhibiting various proteins in these cells. The same would also hold true for the 
cell lines 17-71 and GL-1 where we see lower carbamylation but greater cytotoxicity after 
treatment with the drugs. Thus, carbamylation may not necessarily lead to cell killing.  
 
Even though the hepatocyte samples showed greater carbamylation than the lymphoma cell 
lines after exposure to lomustine and its metabolites, the clinical relevance of this with regards to 
hepatotoxicity is not evident. There is no clear correlation between the carbamylating potential of 
the isocyanates formed from nitrosourea and the cytotoxicity as nitrosoureas that have low 
carbamylating activity retain their antitumor activity (Lemoine et al., 1991). The role of 
carbamylation in the hepatotoxicity caused by lomustine needs to be studied further. Clinical 
studies need to be done in order to compare the carbamylation level in hepatocytes of dogs that 
develop hepatotoxicity after lomustine administration versus those that do not. This can be done 
by collecting needle biopsy samples from the liver of dogs receiving lomustine treatment and 
evaluating the extent of carbamylation. 
 
Finally, in chapter 5 we studied the MGMT enzyme activity and mRNA expression in 
canine lymphoma cell lines and hepatocytes. In our gene induction study, the 17-71 cells did not 
show any significant increase in gene expression after 48 hours of exposure to lomustine and its 
metabolites. There was low MGMT activity in the canine lymphoma cell line 17-71 while the GL-
1 cells did not show any detectable enzyme activity or mRNA expression. The canine hepatocytes 
showed 2-3 fold greater gene expression as compared to 17-71 cells. We showed that MGMT 
mRNA expression in 17-71 cells and canine hepatocytes correlates with the MGMT enzyme 
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activity in these cells.  The MGMT enzyme activity measured in the hepatocytes is conservatively 
greater than 250-350 fmol/mg protein as compared to about 90 fmol/mg protein in 17-71 cells. In 
our MGMT activity assay in hepatocytes, there was over 70% enzymatic cleavage of the substrate 
oligo. This may indicate a sub-optimal enzyme-substrate ratio which could lead to a lower rate of 
reaction thus resulting in underestimation of MGMT activity in hepatocytes. The MGMT activity 
in hepatocytes needs to be verified by redoing the fluorometric assay and using either lower 
amount of cell protein or higher amount of oligo substrate such that the reaction does not consume 
more than 20% of the substrate. 
 
Previously, we have seen that lomustine and its metabolites showed a time and 
concentration dependent toxicity in canine lymphoma cell lines 17-71 and GL-1. However the 
canine hepatocytes did not show any detectable cell killing even 6 days after exposure to the drugs. 
Also, the canine hepatocytes showed lower levels of the cytotoxic O6 guanine adduct as compared 
to the lymphoma cell lines. It is plausible that higher MGMT enzyme activity detected in the 
hepatocytes may be a reason for the lower levels of O6 adducts detected in these cells. The higher 
level of MGMT may cause repair of adducts, and hence contributing to the lower cytotoxicity of 
lomustine and its metabolites in hepatocytes. However this interpretation must be viewed with 
caution, as no significant difference in the O6 adduct levels between 17-71 cells and GL-1 cells 
was noted even though we were unable to detect any MGMT activity in the GL-1 cells.  
 
In our study, the role of MGMT in the cytotoxicity of lomustine and its metabolites is 
inconclusive. One way to study the impact of MGMT on the cytotoxic effects of lomustine and its 
metabolites would be to compare the cytotoxicity of the drugs in cells showing high MGMT level 
120 
 
(in our case, canine glioma cell lines SDT-3 and J3T-Bg or canine hepatcocytes) before and after 
treatment of the cells with an MGMT inhibitor like O6 benzylguanine. O6 benzylguanine acts as a 
pseudosubstrate for MGMT and causes its depletion (Koch et al., 2007).  This will help determine 
if the level of MGMT impacts the cytotoxicity of lomustine and its metabolites. 
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